


PH7442 NP  
10/776828

1. (CURRENTLY AMENDED) A compound of formula (I):



(I)

or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:

ring B is ~~a cyclohexyl group a cycloalkyl group of 3 to 8 carbon atoms wherein the cycloalkyl group is saturated or partially unsaturated; or a heterocycle of 3 to 7 atoms wherein the heterocycle is saturated or partially unsaturated, the heterocycle containing a heteroatom selected from O, S, S(=O), S(=O)<sub>2</sub>, and N(R<sup>4</sup>), the heterocycle optionally containing a C(=O); ring B being substituted with 0-2 R<sup>5</sup>;~~

X is selected from O or S;

Z is ~~-NR<sup>9</sup>-; selected from a bond, NR<sup>8</sup>C(O), NR<sup>8</sup>C(S), NR<sup>8</sup>C(O)NH, NR<sup>8</sup>C(S)NH, NR<sup>8</sup>SO<sub>2</sub>, NR<sup>8</sup>SO<sub>2</sub>NH, C(O)NR<sup>8</sup>, OC(O)NR<sup>8</sup>, NR<sup>8</sup>C(O)O, (CR<sup>15</sup>R<sup>15</sup>)<sub>1</sub>, CR<sup>14</sup>-CR<sup>14</sup>, CR<sup>15</sup>R<sup>15</sup>C(O), C(O)CR<sup>15</sup>R<sup>15</sup>, CR<sup>15</sup>R<sup>15</sup>C(=N OR<sup>16</sup>), O-CR<sup>14</sup>R<sup>14</sup>, CR<sup>14</sup>R<sup>14</sup>-O, O, NR<sup>9</sup>, NR<sup>9</sup>-CR<sup>14</sup>R<sup>14</sup>, CR<sup>14</sup>R<sup>14</sup>-NR<sup>9</sup>, S(O)<sub>p</sub>, S(O)<sub>p</sub>-CR<sup>14</sup>R<sup>14</sup>, CR<sup>14</sup>R<sup>14</sup>-S(O)<sub>p</sub>, and S(O)<sub>p</sub>-NR<sup>9</sup>;~~

wherein neither Z nor R<sup>13</sup> are connected to a carbon atom labeled (b);

PH7442 NP  
10/776828

bond (a) is a single ~~or double~~ bond;

~~alternatively, when n is equal to 2, two atoms labeled (b) may  
join through a double bond,~~

E is selected from  $-S(O)_pCHRe-$ ,  $-CHReNR^e-$ ,  $-C(O)-NR^e-$ ,  
 $-NR^eC(O)NR^e-$ ,  $-SO_2-NR^e-$ , and  $-NR^eSO_2NR^e-$ ;

$R^e$  is independently selected from H and  $C_{1-3}$  alkyl;

$R^1$  is selected from a  $C_{6-10}$  aryl group substituted with 0-5  $R^6$  ~~and  
a 5-10 membered heteroaryl system containing 1-4 heteroatoms  
selected from N, O, and S, substituted with 0-3  $R^6$ ;~~

$R^2$  is selected from a  ~~$C_{6-10}$  aryl group substituted with 0-5  $R^7$  and  
a 5-10 membered heteroaryl system containing 1-4 heteroatoms  
selected from N, O, and S, substituted with 0-3  $R^7$ ;~~

~~$R^4$  is selected from H,  $C_{2-6}$  alkyl,  $C_{3-8}$  alkenyl,  $C_{3-8}$  alkynyl,  
(CRR) $_t$ OH, (CRR) $_t$ SH, (CRR) $_t$ OR $^{4a}$ , (CRR) $_t$ SR $^{4a}$ , (CRR) $_t$ NR $^{4a}$ R $^{4a}$ ,  
(CRR) $_t$ C(O)OH, (CRR) $_t$ C(O)R $^{4b}$ , (CRR) $_t$ C(O)NR $^{4a}$ R $^{4a}$ ,  
(CRR) $_t$ OC(O)NR $^{4a}$ R $^{4a}$ , (CRR) $_t$ NR $^{4a}$ C(O)OR $^{4a}$ , (CRR) $_t$ NR $^{4a}$ C(O)R $^{4b}$ ,  
(CRR) $_t$ C(O)OR $^{4a}$ , (CRR) $_t$ OC(O)R $^{4b}$ , (CRR) $_t$ S(O) $_p$ R $^{4b}$ ,  
(CRR) $_t$ C(O) $_2$ NR $^{4a}$ R $^{4a}$ , (CRR) $_t$ NR $^{4a}$ S(O) $_2$ R $^{4b}$ ,  $C_{1-6}$  haloalkyl, a  
(CRR) $_t$   $C_{3-10}$  carbocyclic residue substituted with 0-3  $R^{4e}$ , and  
a (CRR) $_t$  4-10 membered heterocyclic system containing 1-4  
heteroatoms selected from N, O, and S, substituted with 0-2  
 $R^{4e}$ .~~

~~$R^{4a}$ , at each occurrence, is independently selected from H, methyl  
substituted with 0-1  $R^{4e}$ ,  $C_{2-6}$  alkyl substituted with 0-3  $R^{4e}$ ,~~

PH7442 NP  
10/776828

~~C<sub>3-8</sub> alkenyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-3 R<sup>4e</sup>, a (CH<sub>2</sub>)<sub>x</sub>-C<sub>3-10</sub> carbocyclic residue substituted with 0-4 R<sup>4e</sup>, and a (CHR)<sub>x</sub>-4-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>4e</sup>,~~

~~R<sup>4b</sup>, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-3 R<sup>4e</sup>, a (CH<sub>2</sub>)<sub>x</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-2 R<sup>4e</sup>, and a (CHR)<sub>x</sub>-4-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>4e</sup>,~~

~~R<sup>4e</sup> is independently selected from C(O)R<sup>4b</sup>, C(O)OR<sup>4d</sup>, C(O)NR<sup>4f</sup>R<sup>4f</sup>, and (CH<sub>2</sub>)<sub>x</sub>phenyl,~~

~~R<sup>4d</sup>, at each occurrence, is selected from methyl, CF<sub>3</sub>, C<sub>2-6</sub> alkyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-3 R<sup>4e</sup>, and a C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>4e</sup>,~~

~~R<sup>4e</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>x</sub>-C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>, (CF<sub>3</sub>)<sub>x</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>x</sub>OC<sub>1-5</sub> alkyl, OH, SH, (CH<sub>2</sub>)<sub>x</sub>SC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>x</sub>NR<sup>4f</sup>R<sup>4f</sup>, C(O)R<sup>4i</sup>, C(O)OR<sup>4j</sup>, C(O)NR<sup>4h</sup>R<sup>4h</sup>, OC(O)NR<sup>4h</sup>R<sup>4h</sup>, NR<sup>4h</sup>C(O)NR<sup>4h</sup>R<sup>4h</sup>, NR<sup>4h</sup>C(O)OR<sup>4j</sup>, and (CH<sub>2</sub>)<sub>x</sub>phenyl,~~

~~R<sup>4f</sup>, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, and phenyl,~~

PH7442 NP

10/776828

~~R<sup>4b</sup>, at each occurrence, is independently selected from H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, and a (CH<sub>2</sub>)<sub>x</sub>-C<sub>3-10</sub> carbocyclic,~~

~~R<sup>4c</sup>, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, and a (CH<sub>2</sub>)<sub>x</sub>-C<sub>3-6</sub> carbocyclic residue,~~

~~R<sup>4d</sup>, at each occurrence, is selected from CF<sub>3</sub>, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, and a C<sub>3-10</sub> carbocyclic residue,~~

R<sup>5</sup>, at each occurrence, is independently selected from H, =O, C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CRR)<sub>x</sub>OH, (CRR)<sub>x</sub>SH, (CRR)<sub>x</sub>OR<sup>5d</sup>, (CRR)<sub>x</sub>SR<sup>5d</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>N(→O)R<sup>5a</sup>R<sup>5a</sup>, N<sub>3</sub>, (CRR)<sub>x</sub>C(O)OH, (CRR)<sub>x</sub>C(O)R<sup>5b</sup>, (CRR)<sub>x</sub>C(O)NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>C(O)R<sup>5b</sup>, (CRR)<sub>x</sub>OC(O)NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>C(O)OR<sup>5d</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>C(O)NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>C(O)H, (CRR)<sub>x</sub>C(O)OR<sup>5d</sup>, (CRR)<sub>x</sub>OC(O)R<sup>5b</sup>, (CRR)<sub>x</sub>S(O)<sub>p</sub>R<sup>5b</sup>, (CRR)<sub>x</sub>S(O)<sub>2</sub>NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>S(O)<sub>2</sub>R<sup>5b</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>S(O)<sub>2</sub>NR<sup>5a</sup>R<sup>5a</sup>, C<sub>1-6</sub> haloalkyl, a (CRR)<sub>x</sub>-C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>5c</sup>, and a (CRR)<sub>x</sub>-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>5c</sup>;

R<sup>5a</sup>, at each occurrence, is independently selected from H, methyl substituted with 0-1 R<sup>5g</sup>, C<sub>2-6</sub> alkyl substituted with 0-2 R<sup>5e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-2 R<sup>5e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-2 R<sup>5e</sup>, a (CH<sub>2</sub>)<sub>x</sub>-C<sub>3-10</sub> carbocyclic residue substituted with 0-5 R<sup>5e</sup>, and a (CH<sub>2</sub>)<sub>x</sub>-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>5e</sup>;

PH7442 NP  
10/776828

R<sup>5b</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl substituted with 0-3 R<sup>5e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-2 R<sup>5e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-2 R<sup>5e</sup>, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-2 R<sup>5e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>5e</sup>;

R<sup>5c</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> cycloalkyl, Cl, Br, I, F, (CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, NO<sub>2</sub>, CN, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>OH, (CH<sub>2</sub>)<sub>r</sub>OC<sub>1-4</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>SC<sub>1-4</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>C(O)OH, (CH<sub>2</sub>)<sub>r</sub>C(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>C(O)NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>OC(O)NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>C(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>C(O)OC<sub>1-4</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>C(O)OC<sub>1-4</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>OC(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>C(=NR<sup>5f</sup>)NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>S(O)<sub>p</sub>R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>NHC(=NR<sup>5f</sup>)NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>S(O)<sub>2</sub>NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>S(O)<sub>2</sub>R<sup>5b</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl substituted with 0-3 R<sup>5e</sup>;

R<sup>5d</sup>, at each occurrence, is selected from methyl, CF<sub>3</sub>, C<sub>2-6</sub> alkyl substituted with 0-2 R<sup>5e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-2 R<sup>5e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-2 R<sup>5e</sup>, and a C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>5e</sup>;

R<sup>5e</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>, (CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>r</sub>OC<sub>1-5</sub> alkyl, OH, SH, (CH<sub>2</sub>)<sub>r</sub>SC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>R<sup>5f</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl;

R<sup>5f</sup>, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl, and C<sub>3-6</sub> cycloalkyl;

PH7442 NP  
10/776828

R<sup>5g</sup> is independently selected from -C(O)R<sup>5b</sup>, -C(O)OR<sup>5d</sup>,  
-C(O)NR<sup>5f</sup>R<sup>5f</sup>, -CN, and (CH<sub>2</sub>)<sub>x</sub>phenyl;

R, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl substituted  
with R<sup>5e</sup>, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>x</sub>C<sub>3-6</sub> cycloalkyl,  
and (CH<sub>2</sub>)<sub>x</sub>phenyl substituted with R<sup>5e</sup>;

R<sup>6</sup>, at each occurrence, is selected from C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl,  
C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>x</sub>C<sub>3-6</sub> cycloalkyl, Cl, Br, I, F, NO<sub>2</sub>, CN,  
(CR'R')<sub>x</sub>NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>x</sub>OH, (CR'R')<sub>x</sub>O(CR'R')<sub>x</sub>R<sup>6d</sup>, (CR'R')<sub>x</sub>SH,  
(CR'R')<sub>x</sub>C(O)H, (CR'R')<sub>x</sub>S(CR'R')<sub>x</sub>R<sup>6d</sup>, (CR'R')<sub>x</sub>SC(O)(CR'R')<sub>x</sub>R<sup>6b</sup>,  
(CR'R')<sub>x</sub>C(O)OH, (CR'R')<sub>x</sub>C(O)(CR'R')<sub>x</sub>R<sup>6b</sup>, (CR'R')<sub>x</sub>NR<sup>6a</sup>R<sup>6a</sup>,  
(CR'R')<sub>x</sub>C(O)NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>x</sub>NR<sup>6f</sup>C(O)(CR'R')<sub>x</sub>R<sup>6b</sup>,  
(CR'R')<sub>x</sub>C(O)O(CR'R')<sub>x</sub>R<sup>6d</sup>, (CR'R')<sub>x</sub>OC(O)(CR'R')<sub>x</sub>R<sup>6b</sup>,  
(CR'R')<sub>x</sub>OC(O)NR<sup>6a</sup>(CR'R')<sub>x</sub>R<sup>6d</sup>, (CR'R')<sub>x</sub>NR<sup>6a</sup>C(O)NR<sup>6a</sup>(CR'R')<sub>x</sub>R<sup>6d</sup>,  
(CR'R')<sub>x</sub>NR<sup>6a</sup>C(S)NR<sup>6a</sup>(CR'R')<sub>x</sub>R<sup>6d</sup>, (CR'R')<sub>x</sub>NR<sup>6f</sup>C(O)O(CR'R')<sub>x</sub>R<sup>6b</sup>,  
(CR'R')<sub>x</sub>C(=NR<sup>6f</sup>)NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>x</sub>NHC(=NR<sup>6f</sup>)NR<sup>6f</sup>R<sup>6f</sup>,  
(CR'R')<sub>x</sub>S(O)<sub>p</sub>(CR'R')<sub>x</sub>R<sup>6b</sup>, (CR'R')<sub>x</sub>S(O)<sub>2</sub>NR<sup>6a</sup>R<sup>6a</sup>,  
(CR'R')<sub>x</sub>NR<sup>6f</sup>S(O)<sub>2</sub>NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>x</sub>NR<sup>6f</sup>S(O)<sub>2</sub>(CR'R')<sub>x</sub>R<sup>6b</sup>, C<sub>1-6</sub>  
haloalkyl, C<sub>2-8</sub> alkenyl substituted with 0-3 R', C<sub>2-8</sub> alkynyl  
substituted with 0-3 R', (CR'R')<sub>x</sub>phenyl substituted with 0-3  
R<sup>6e</sup>, and a (CH<sub>2</sub>)<sub>x</sub>-5-6 membered heterocyclic system containing  
1-2 heteroatoms selected from N, O, and S, substituted with  
0-2 R<sup>6e</sup>;

alternatively, two R<sup>6</sup> on adjacent atoms on R<sup>1</sup> may join to form a  
cyclic acetal;

R<sup>6a</sup>, at each occurrence, is selected from H, methyl substituted  
with 0-1 R<sup>6g</sup>, C<sub>2-6</sub> alkyl substituted with 0-2 R<sup>6e</sup>, C<sub>3-8</sub>  
alkenyl substituted with 0-2 R<sup>6e</sup>, C<sub>3-8</sub> alkynyl substituted

PH7442 NP

10/776828

with 0-2  $R^{6e}$ , a  $(CH_2)_r$ -C<sub>3-10</sub> carbocyclic residue substituted with 0-5  $R^{6e}$ , and a  $(CH_2)_r$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2  $R^{6e}$ ;

$R^{6b}$ , at each occurrence, is selected from H, C<sub>1-6</sub> alkyl substituted with 0-2  $R^{6e}$ , C<sub>3-8</sub> alkenyl substituted with 0-2  $R^{6e}$ , C<sub>3-8</sub> alkynyl substituted with 0-2  $R^{6e}$ , a  $(CH_2)_r$ -C<sub>3-6</sub> carbocyclic residue substituted with 0-3  $R^{6e}$ , and a  $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2  $R^{6e}$ ;

$R^{6d}$ , at each occurrence, is selected from C<sub>3-8</sub> alkenyl substituted with 0-2  $R^{6e}$ , C<sub>3-8</sub> alkynyl substituted with 0-2  $R^{6e}$ , methyl, CF<sub>3</sub>, C<sub>2-6</sub> alkyl substituted with 0-3  $R^{6e}$ , C<sub>2-4</sub> haloalkyl, a  $(CH_2)_r$ -C<sub>3-10</sub> carbocyclic residue substituted with 0-3  $R^{6e}$ , and a  $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $R^{6e}$ ;

$R^{6e}$ , at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl,  $(CH_2)_r$ -C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>,  $(CF_2)_r$ -CF<sub>3</sub>,  $(CH_2)_r$ -OC<sub>1-5</sub> alkyl, OH, SH,  $(CH_2)_r$ -SC<sub>1-5</sub> alkyl,  $(CH_2)_r$ -NR<sup>6f</sup>R<sup>6f</sup>, and  $(CH_2)_r$ -phenyl;

$R^{6f}$ , at each occurrence, is selected from H, C<sub>1-5</sub> alkyl, and C<sub>3-6</sub> cycloalkyl, and phenyl;

$R^{6g}$  is independently selected from -C(O)R<sup>6b</sup>, -C(O)OR<sup>6d</sup>, -C(O)NR<sup>6f</sup>R<sup>6f</sup>, and  $(CH_2)_r$ -phenyl;

PH7442 NP

10/776828

$R^7$ , at each occurrence, is selected from  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl,  $(CH_2)_x C_{3-6}$  cycloalkyl, Cl, Br, I, F,  $NO_2$ , CN,  $(CR'R')_x NR^{7a} R^{7a}$ ,  $(CR'R')_x OH$ ,  $(CR'R')_x O(CR'R')_x R^{7d}$ ,  $(CR'R')_x SH$ ,  $(CR'R')_x C(O)H$ ,  $(CR'R')_x S(CR'R')_x R^{7d}$ ,  $(CR'R')_x C(O)OH$ ,  $(CR'R')_x C(O)(CR'R')_x R^{7b}$ ,  $(CR'R')_x C(O)NR^{7a} R^{7a}$ ,  $(CR'R')_x NR^{7f} C(O)(CR'R')_x R^{7b}$ ,  $(CR'R')_x C(O)O(CR'R')_x R^{7d}$ ,  $(CR'R')_x OC(O)(CR'R')_x R^{7b}$ ,  $(CR'R')_x OC(O)NR^{7a}(CR'R')_x R^{7a}$ ,  $(CR'R')_x NR^{7a} C(O)NR^{7a}(CR'R')_x R^{7a}$ ,  $(CR'R')_x NR^{7f} C(O)O(CR'R')_x R^{7d}$ ,  $(CR'R')_x C(=NR^{7f})NR^{7a} R^{7a}$ ,  $(CR'R')_x NHC(=NR^{7f})NR^{7f} R^{7f}$ ,  $(CR'R')_x S(O)_p(CR'R')_x R^{7b}$ ,  $(CR'R')_x S(O)_2 NR^{7a} R^{7a}$ ,  $(CR'R')_x NR^{7a} S(O)_2 NR^{7a} R^{7a}$ ,  $(CR'R')_x NR^{7f} S(O)_2(CR'R')_x R^{7b}$ ,  $C_{1-6}$  haloalkyl,  $C_{2-8}$  alkenyl substituted with 0-3  $R'$ ,  $C_{2-8}$  alkynyl substituted with 0-3  $R'$ ,  $(CR'R')_x C_{3-10}$  carbocyclic residue and  $(CR'R')_x$  phenyl substituted with 0-3  $R^{7e}$ ;

alternatively, two  $R^7$  on adjacent atoms on  $R^2$  may join to form a cyclic acetal;

$R^{7a}$ , at each occurrence, is independently selected from H, methyl substituted with 0-1  $R^{7g}$ ,  $C_{2-6}$  alkyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkenyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkynyl substituted with 0-2  $R^{7e}$ , a  $(CH_2)_x C_{3-10}$  carbocyclic residue substituted with 0-5  $R^{7e}$ , and a  $(CH_2)_{x-5-10}$  membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2  $R^{7e}$ ;

$R^{7b}$ , at each occurrence, is selected from  $C_{1-6}$  alkyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkenyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkynyl substituted with 0-2  $R^{7e}$ , a  $(CH_2)_x C_{3-6}$  carbocyclic residue substituted with 0-3  $R^{7e}$ , and a  $(CH_2)_{x-5-6}$  membered



PH7442 NP  
10/776828

heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>7e</sup>;

R<sup>7d</sup>, at each occurrence, is selected from C<sub>3-8</sub> alkenyl substituted with 0-2 R<sup>7e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-2 R<sup>7e</sup>, methyl, CF<sub>3</sub>, C<sub>2-4</sub> haloalkyl, C<sub>2-6</sub> alkyl substituted with 0-3 R<sup>7e</sup>, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>7e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>7e</sup>;

R<sup>7e</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>, (CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>r</sub>OC<sub>1-5</sub> alkyl, OH, SH, C(O)OC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>SC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>NR<sup>7f</sup>R<sup>7f</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl;

R<sup>7f</sup>, at each occurrence, is selected from H, C<sub>1-5</sub> alkyl, and C<sub>3-6</sub> cycloalkyl, and phenyl;

R<sup>7g</sup> is independently selected from -C(O)R<sup>7b</sup>, -C(O)OR<sup>7d</sup>, -C(O)NR<sup>7f</sup>R<sup>7f</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl;

R', at each occurrence, is selected from H, C<sub>1-6</sub> alkyl substituted with R<sup>6e</sup>, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> cycloalkyl, and (CH<sub>2</sub>)<sub>r</sub>phenyl substituted with R<sup>6e</sup>;

~~R<sup>6</sup> is selected from H, C<sub>1-4</sub> alkyl, and C<sub>3-4</sub> cycloalkyl,~~

R<sup>9</sup> is selected from H, C<sub>1-4</sub> alkyl, C<sub>3-4</sub> cycloalkyl, -C(O)H, and -C(O)-C<sub>1-4</sub>alkyl;

PH7442 NP  
10/776828

R<sup>10</sup> is independently selected from H, and C<sub>1-4</sub>alkyl substituted with 0-1 R<sup>10b</sup>, alternatively, two R<sup>10</sup> form =O;

R<sup>10b</sup>, at each occurrence, is independently selected from -OH, -SH, -NR<sup>10c</sup>R<sup>10c</sup>, -C(O)NR<sup>10c</sup>R<sup>10c</sup>, and -NHC(O)R<sup>10c</sup>;

R<sup>10c</sup> is selected from H, C<sub>1-4</sub> alkyl and C<sub>3-6</sub> cycloalkyl;

R<sup>11</sup> is selected from H, C<sub>1-4</sub> alkyl, (CHR)<sub>q</sub>OH, (CHR)<sub>q</sub>SH, (CHR)<sub>q</sub>OR<sup>11d</sup>, (CHR)<sub>q</sub>S(O)<sub>p</sub>R<sup>11d</sup>, (CHR)<sub>r</sub>C(O)R<sup>11b</sup>, (CHR)<sub>r</sub>NR<sup>11a</sup>R<sup>11a</sup>, (CHR)<sub>r</sub>C(O)NR<sup>11a</sup>R<sup>11a</sup>, (CHR)<sub>r</sub>C(O)NR<sup>11a</sup>OR<sup>11d</sup>, (CHR)<sub>q</sub>NR<sup>11a</sup>C(O)R<sup>11b</sup>, (CHR)<sub>q</sub>NR<sup>11a</sup>C(O)OR<sup>11d</sup>, (CHR)<sub>q</sub>OC(O)NR<sup>11a</sup>R<sup>11a</sup>, (CHR)<sub>r</sub>C(O)OR<sup>11d</sup>, a (CHR)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-5 R<sup>11e</sup>, and a (CHR)<sub>r</sub>-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>11e</sup>;

R<sup>11a</sup>, at each occurrence, is independently selected from H, C<sub>1-4</sub> alkyl, C<sub>3-4</sub> alkenyl, C<sub>3-4</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>C<sub>3-6</sub> cycloalkyl, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-5 R<sup>11e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>11e</sup>;

R<sup>11b</sup>, at each occurrence, is independently selected from C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-2 R<sup>11e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>11e</sup>;

PH7442 NP  
10/776828

R<sup>11d</sup>, at each occurrence, is independently selected from H, methyl, -CF<sub>3</sub>, C<sub>2-4</sub> alkyl, C<sub>3-6</sub> alkenyl, C<sub>3-6</sub> alkynyl, a C<sub>3-6</sub> carbocyclic residue substituted with 0-3 R<sup>11e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>11e</sup>;

R<sup>11e</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>, (CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>r</sub>OC<sub>1-5</sub> alkyl, OH, -O-C<sub>1-6</sub> alkyl, SH, (CH<sub>2</sub>)<sub>r</sub>SC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>NR<sup>11f</sup>R<sup>11f</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl;

R<sup>11f</sup>, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl, and C<sub>3-6</sub> cycloalkyl;

R<sup>12</sup> is selected from H, C<sub>1-4</sub> alkyl, (CHR)<sub>q</sub>OH, (CHR)<sub>q</sub>SH, (CHR)<sub>q</sub>OR<sup>12d</sup>, (CHR)<sub>q</sub>S(O)<sub>p</sub>R<sup>12d</sup>, (CHR)<sub>r</sub>C(O)R<sup>12b</sup>, (CHR)<sub>r</sub>NR<sup>12a</sup>R<sup>12a</sup>, (CHR)<sub>r</sub>C(O)NR<sup>12a</sup>R<sup>12a</sup>, (CHR)<sub>r</sub>C(O)NR<sup>12a</sup>OR<sup>12d</sup>, (CHR)<sub>q</sub>NR<sup>12a</sup>C(O)R<sup>12b</sup>, (CHR)<sub>q</sub>NR<sup>12a</sup>C(O)OR<sup>12d</sup>, (CHR)<sub>q</sub>OC(O)NR<sup>12a</sup>R<sup>12a</sup>, (CHR)<sub>r</sub>C(O)OR<sup>12d</sup>, a (CHR)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-5 R<sup>12e</sup>, and a (CHR)<sub>r</sub>-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>12e</sup>;

R<sup>12a</sup>, at each occurrence, is independently selected from H, C<sub>1-4</sub> alkyl, C<sub>3-4</sub> alkenyl, C<sub>3-4</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>C<sub>3-6</sub> cycloalkyl, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-5 R<sup>12e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>12e</sup>;

PH7442 NP

10/776828

$R^{12b}$ , at each occurrence, is independently selected from  $C_{1-4}$  alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl, a  $(CH_2)_r$ - $C_{3-6}$  carbocyclic residue substituted with 0-2  $R^{12e}$ , and a  $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $R^{12e}$ ;

$R^{12d}$ , at each occurrence, is independently selected from H, methyl,  $-CF_3$ ,  $C_{2-4}$  alkyl,  $C_{3-6}$  alkenyl,  $C_{3-6}$  alkynyl, a  $C_{3-6}$  carbocyclic residue substituted with 0-3  $R^{12e}$ , and a  $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $R^{12e}$ ;

$R^{12e}$ , at each occurrence, is selected from  $C_{1-6}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl,  $C_{3-6}$  cycloalkyl, Cl, F, Br, I, CN,  $NO_2$ ,  $(CF_2)_rCF_3$ ,  $(CH_2)_rOC_{1-5}$  alkyl, OH,  $-O-C_{1-6}$  alkyl, SH,  $(CH_2)_rSC_{1-5}$  alkyl,  $(CH_2)_rNR^{12f}R^{12f}$ , and  $(CH_2)_r$ phenyl;

$R^{12f}$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, and  $C_{3-6}$  cycloalkyl;

$R^{13}$ , at each occurrence, is independently selected from H, and  $C_{1-4}$ alkyl substituted with 0-1  $R^{13b}$ ,  $-OH$ ,  $-NH_2$ , F, Cl, Br, I,  $-OR^{13a}$ ,  $-N(R^{13a})_2$ , and  $C_{1-4}$  alkyl substituted with 0-3  $R^{13b}$ ;

$R^{13a}$  is selected from H,  $C_{1-4}$  alkyl and  $C_{3-6}$  cycloalkyl;

$R^{13b}$ , at each occurrence, is independently selected from  $-OH$ ,  $-SH$ ,  $-NR^{13c}R^{13c}$ ,  $-C(O)NR^{13c}R^{13c}$ , and  $-NHC(O)R^{13c}$ ;

PH7442 NP

10/776828

$R^{13c}$  is selected from H,  $C_{1-4}$  alkyl and  $C_{3-6}$  cycloalkyl;

~~$R^{14}$ , at each occurrence, is independently selected from H and  $C_{1-4}$  alkyl;~~

~~alternatively, two  $R^{14}$ s, along with the carbon atom to which they are attached, join to form a  $C_{3-6}$  carbocyclic ring;~~

~~$R^{15}$ , at each occurrence, is independently selected from H,  $C_{1-4}$  alkyl, OH,  $NH_2$ ,  $O$   $C_{1-4}$  alkyl,  $NR^{15a}R^{15a}$ ,  $C(O)NR^{15a}R^{15a}$ ,  $NR^{15a}C(O)R^{15b}$ ,  $NR^{15a}C(O)OR^{15d}$ ,  $OC(O)NR^{15a}R^{15a}$ , and  $(CHR)_2C(O)OR^{15d}$ ;~~

~~alternatively, two  $R^{15}$ s, along with the carbon atom or atoms to which they are attached, join to form a  $C_{3-6}$  carbocyclic ring;~~

~~$R^{15a}$ , at each occurrence, is independently selected from H, and  $C_{1-4}$  alkyl;~~

~~$R^{15b}$ , at each occurrence, is independently selected from  $C_{1-4}$  alkyl,  $C_{3-6}$  alkenyl, and  $C_{3-6}$  alkynyl;~~

~~$R^{15d}$ , at each occurrence, is independently selected from  $C_{1-4}$  alkyl,  $C_{3-6}$  alkenyl, and  $C_{3-6}$  alkynyl;~~

~~$R^{16}$  is selected from  $C_{1-4}$  alkyl;~~

1 is selected from 1, 2 and 3;

PH7442 NP  
10/776828

n is 1; ~~selected from 0, 1, 2, and 3;~~

m is selected from 0 and 1;

p, at each occurrence, is independently selected from 0, 1, and 2;


q, at each occurrence, is independently selected from 1, 2, 3, and 4;

r, at each occurrence, is independently selected from 0, 1, 2, 3, and 4;

t, at each occurrence, is independently selected from 2, 3, and 4;

s is selected from 0 and 1.

2. (CURRENTLY AMENDED) A compound of claim 1, wherein the compound is of formula (I):



(I)

or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:

ring B is a cyclohexyl group ~~cycloalkyl group of 3 to 8 carbon atoms wherein the cycloalkyl group is saturated or partially unsaturated; or a heterocycle of 3 to 7 atoms wherein the heterocycle is saturated or partially unsaturated, the heterocycle containing a heteroatom selected from O, S,~~

PH7442 NP

10/776828

~~S(=O)~~, ~~S(=O)<sub>2</sub>~~, and ~~N(R<sup>4</sup>)~~, the heterocycle optionally containing a ~~C(O)~~; ring B being substituted with 0-2 R<sup>5</sup>;

X is selected from O or S;

Z is ~~NR<sup>3</sup>~~; selected from a bond, ~~NR<sup>3</sup>C(O)~~, ~~NR<sup>3</sup>C(S)~~, ~~NR<sup>3</sup>C(O)NH~~, ~~NR<sup>3</sup>C(S)NH~~, ~~NR<sup>3</sup>SO<sub>2</sub>~~, ~~NR<sup>3</sup>SO<sub>2</sub>NH~~, ~~C(O)NR<sup>3</sup>~~, ~~OC(O)NR<sup>3</sup>~~, ~~NR<sup>3</sup>C(O)O~~, ~~(CR<sup>15</sup>R<sup>15</sup>)<sub>1</sub>~~, ~~CR<sup>14</sup>CR<sup>14</sup>~~, ~~CR<sup>15</sup>R<sup>15</sup>C(O)~~, ~~C(O)CR<sup>15</sup>R<sup>15</sup>~~, ~~CR<sup>15</sup>R<sup>15</sup>C(-N OR<sup>16</sup>)~~, ~~O CR<sup>14</sup>R<sup>14</sup>~~, ~~CR<sup>14</sup>R<sup>14</sup>O~~, ~~O~~, ~~NR<sup>3</sup>~~, ~~NR<sup>3</sup>CR<sup>14</sup>R<sup>14</sup>~~, ~~CR<sup>14</sup>R<sup>14</sup>NR<sup>3</sup>~~, ~~S(O)<sub>p</sub>~~, ~~S(O)<sub>p</sub>CR<sup>14</sup>R<sup>14</sup>~~, ~~CR<sup>14</sup>R<sup>14</sup>S(O)<sub>p</sub>~~, and ~~S(O)<sub>p</sub>NR<sup>3</sup>~~,

wherein neither Z nor R<sup>13</sup> are connected to a carbon atom labeled (b);

bond (a) is a single ~~or double~~ bond;

~~alternatively, when n is equal to 2, two atoms labeled (b) may join through a double bond;~~

E is selected from ~~S(O)<sub>p</sub>CHRe-~~, ~~CHReNRe-~~, ~~C(O)-NRe-~~, ~~NReC(O)NRe-~~, ~~SO<sub>2</sub>-NRe-~~, and ~~NReSO<sub>2</sub>NRe-~~;

Re is independently selected from H and C<sub>1-3</sub> alkyl;

R<sup>1</sup> is selected from a C<sub>6-10</sub> aryl group substituted with 0-5 R<sup>6</sup> and ~~a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>6</sup>;~~

R<sup>2</sup> is selected from ~~a C<sub>6-10</sub> aryl group substituted with 0-5 R<sup>7</sup>~~ and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>7</sup>;

PH7442 NP

10/776828

~~R<sup>4</sup> is selected from H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, (CRR)<sub>x</sub>OH, (CRR)<sub>x</sub>SH, (CRR)<sub>x</sub>OR<sup>4d</sup>, (CHR)<sub>x</sub>SR<sup>4d</sup>, (CRR)<sub>x</sub>NR<sup>4a</sup>R<sup>4a</sup>, (CRR)<sub>x</sub>C(O)OH, (CRR)<sub>x</sub>C(O)R<sup>4b</sup>, (CRR)<sub>x</sub>C(O)NR<sup>4a</sup>R<sup>4a</sup>, (CRR)<sub>x</sub>OC(O)NR<sup>4a</sup>R<sup>4a</sup>, (CRR)<sub>x</sub>NR<sup>4a</sup>C(O)OR<sup>4d</sup>, (CRR)<sub>x</sub>NR<sup>4a</sup>C(O)R<sup>4b</sup>, (CRR)<sub>x</sub>C(O)OR<sup>4d</sup>, (CRR)<sub>x</sub>OC(O)R<sup>4b</sup>, (CRR)<sub>x</sub>C(O)<sub>p</sub>R<sup>4b</sup>, (CRR)<sub>x</sub>C(O)<sub>2</sub>NR<sup>4a</sup>R<sup>4a</sup>, (CRR)<sub>x</sub>NR<sup>4a</sup>S(O)<sub>2</sub>R<sup>4b</sup>, C<sub>1-6</sub> haloalkyl, a (CRR)<sub>x</sub>-C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>4e</sup>, and a (CHR)<sub>x</sub>-4-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>4e</sup>.~~

~~R<sup>4a</sup>, at each occurrence, is independently selected from H, methyl substituted with 0-1 R<sup>4e</sup>, C<sub>2-6</sub> alkyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-3 R<sup>4e</sup>, a (CH<sub>2</sub>)<sub>x</sub>-C<sub>3-10</sub> carbocyclic residue substituted with 0-4 R<sup>4e</sup>, and a (CHR)<sub>x</sub>-4-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>4e</sup>.~~

~~R<sup>4b</sup>, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-3 R<sup>4e</sup>, a (CH<sub>2</sub>)<sub>x</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-2 R<sup>4e</sup>, and a (CHR)<sub>x</sub>-4-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>4e</sup>.~~

~~R<sup>4e</sup> is independently selected from C(O)R<sup>4b</sup>, C(O)OR<sup>4d</sup>, C(O)NR<sup>4f</sup>R<sup>4f</sup>, and (CH<sub>2</sub>)<sub>x</sub>phenyl.~~



PH7442 NP  
10/776828

~~R<sup>4d</sup>, at each occurrence, is selected from methyl, CF<sub>3</sub>, C<sub>2-6</sub> alkyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-3 R<sup>4e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-3 R<sup>4e</sup>, and a C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>4e</sup>,~~

~~R<sup>4e</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>x</sub>C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>, (CF<sub>2</sub>)<sub>x</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>x</sub>OC<sub>1-5</sub> alkyl, OH, SH, (CH<sub>2</sub>)<sub>x</sub>SC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>x</sub>NR<sup>4f</sup>R<sup>4f</sup>, C(O)R<sup>4i</sup>, C(O)OR<sup>4j</sup>, C(O)NR<sup>4h</sup>R<sup>4h</sup>, OC(O)NR<sup>4h</sup>R<sup>4h</sup>, NR<sup>4h</sup>C(O)NR<sup>4h</sup>R<sup>4h</sup>, NR<sup>4h</sup>C(O)OR<sup>4j</sup>, and (CH<sub>2</sub>)<sub>x</sub>phenyl,~~

~~R<sup>4f</sup>, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, and phenyl,~~

~~R<sup>4h</sup>, at each occurrence, is independently selected from H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, and a (CH<sub>2</sub>)<sub>x</sub>C<sub>3-10</sub> carbocyclic,~~

~~R<sup>4i</sup>, at each occurrence, is selected from H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, and a (CH<sub>2</sub>)<sub>x</sub>C<sub>3-6</sub> carbocyclic residue,~~

~~R<sup>4j</sup>, at each occurrence, is selected from CF<sub>3</sub>, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, and a C<sub>3-10</sub> carbocyclic residue,~~

R<sup>5</sup>, at each occurrence, is independently selected from H, =O, C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CRR)<sub>x</sub>OH, (CRR)<sub>x</sub>SH, (CRR)<sub>x</sub>OR<sup>5d</sup>, (CRR)<sub>x</sub>SR<sup>5d</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>C(O)OH, (CRR)<sub>x</sub>C(O)R<sup>5b</sup>, (CRR)<sub>x</sub>C(O)NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>C(O)R<sup>5b</sup>, (CRR)<sub>x</sub>OC(O)NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>C(O)OR<sup>5d</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>C(O)NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>C(O)H, (CRR)<sub>x</sub>C(O)OR<sup>5d</sup>, (CRR)<sub>x</sub>OC(O)R<sup>5b</sup>, (CRR)<sub>x</sub>S(O)<sub>p</sub>R<sup>5b</sup>, (CRR)<sub>x</sub>S(O)<sub>2</sub>NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>x</sub>NR<sup>5a</sup>S(O)<sub>2</sub>R<sup>5b</sup>,

PH7442 NP  
10/776828

(CRR)<sub>r</sub>NR<sup>5a</sup>SR<sup>5a</sup>, C<sub>1-6</sub> haloalkyl, a (CRR)<sub>r</sub>-C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>5c</sup>, and a (CRR)<sub>r</sub>-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>5c</sup>;

R<sup>5a</sup>, at each occurrence, is independently selected from H, methyl substituted with 0-1 R<sup>5g</sup>, C<sub>2-6</sub> alkyl substituted with 0-2 R<sup>5e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-2 R<sup>5e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-2 R<sup>5e</sup>, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-10</sub> carbocyclic residue substituted with 0-5 R<sup>5e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>5e</sup>;

R<sup>5b</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl substituted with 0-3 R<sup>5e</sup>, C<sub>3-8</sub> alkenyl substituted with 0-2 R<sup>5e</sup>, C<sub>3-8</sub> alkynyl substituted with 0-2 R<sup>5e</sup>, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-2 R<sup>5e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>5e</sup>;

R<sup>5c</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> cycloalkyl, Cl, Br, I, F, (CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, NO<sub>2</sub>, CN, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>OH, (CH<sub>2</sub>)<sub>r</sub>OC<sub>1-4</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>SC<sub>1-4</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>C(O)OH, (CH<sub>2</sub>)<sub>r</sub>C(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>C(O)NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>OC(O)NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>C(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>C(O)OC<sub>1-4</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>C(O)OC<sub>1-4</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>OC(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>C(=NR<sup>5f</sup>)NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>S(O)<sub>p</sub>R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>NHC(=NR<sup>5f</sup>)NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>S(O)<sub>2</sub>NR<sup>5f</sup>R<sup>5f</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5f</sup>S(O)<sub>2</sub>R<sup>5b</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl substituted with 0-3 R<sup>5e</sup>;

PH7442 NP  
10/776828

$R^{5d}$ , at each occurrence, is selected from methyl,  $CF_3$ ,  $C_{2-6}$  alkyl substituted with 0-2  $R^{5e}$ ,  $C_{3-8}$  alkenyl substituted with 0-2  $R^{5e}$ ,  $C_{3-8}$  alkynyl substituted with 0-2  $R^{5e}$ , and a  $C_{3-10}$  carbocyclic residue substituted with 0-3  $R^{5e}$ ;

$R^{5e}$ , at each occurrence, is selected from  $C_{1-6}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl,  $C_{3-6}$  cycloalkyl, Cl, F, Br, I, CN,  $NO_2$ ,  $(CF_2)_rCF_3$ ,  $(CH_2)_rOC_{1-5}$  alkyl, OH, SH,  $(CH_2)_rSC_{1-5}$  alkyl,  $(CH_2)_rNR^{5f}R^{5f}$ , and  $(CH_2)_rphenyl$ ;

$R^{5f}$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, and  $C_{3-6}$  cycloalkyl;

$R^{5g}$  is independently selected from  $-C(O)R^{5b}$ ,  $-C(O)OR^{5d}$ ,  $-C(O)NR^{5f}R^{5f}$ , and  $(CH_2)_rphenyl$ ;

R, at each occurrence, is selected from H,  $C_{1-6}$  alkyl substituted with  $R^{5e}$ ,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl,  $(CH_2)_rC_{3-6}$  cycloalkyl, and  $(CH_2)_rphenyl$  substituted with  $R^{5e}$ ;

$R^6$ , at each occurrence, is selected from  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl,  $(CH_2)_rC_{3-6}$  cycloalkyl, Cl, Br, I, F,  $NO_2$ , CN,  $(CR'R')_rNR^{6a}R^{6a}$ ,  $(CR'R')_rOH$ ,  $(CR'R')_rO(CR'R')_rR^{6d}$ ,  $(CR'R')_rSH$ ,  $(CR'R')_rC(O)H$ ,  $(CR'R')_rS(CR'R')_rR^{6d}$ ,  $(CR'R')_rSC(O)(CR'R')_rR^{6b}$ ,  $(CR'R')_rC(O)OH$ ,  $(CR'R')_rC(O)(CR'R')_rR^{6b}$ ,  $(CR'R')_rNR^{6a}R^{6a}$ ,  $(CR'R')_rC(O)NR^{6a}R^{6a}$ ,  $(CR'R')_rNR^{6f}C(O)(CR'R')_rR^{6b}$ ,  $(CR'R')_rC(O)O(CR'R')_rR^{6d}$ ,  $(CR'R')_rOC(O)(CR'R')_rR^{6b}$ ,  $(CR'R')_rOC(O)NR^{6a}(CR'R')_rR^{6d}$ ,  $(CR'R')_rNR^{6a}C(O)NR^{6a}(CR'R')_rR^{6d}$ ,  $(CR'R')_rNR^{6a}C(S)NR^{6a}(CR'R')_rR^{6d}$ ,  $(CR'R')_rNR^{6f}C(O)O(CR'R')_rR^{6b}$ ,  $(CR'R')_rC(=NR^{6f})NR^{6a}R^{6a}$ ,  $(CR'R')_rNHC(=NR^{6f})NR^{6f}R^{6f}$ ,  $(CR'R')_rS(O)_p(CR'R')_rR^{6b}$ ,  $(CR'R')_rS(O)_2NR^{6a}R^{6a}$ ,

PH7442 NP  
10/776828

$(\text{CR}'\text{R}')_r\text{NR}^{6f}\text{S}(\text{O})_2\text{NR}^{6a}\text{R}^{6a}$ ,  $(\text{CR}'\text{R}')_r\text{NR}^{6f}\text{S}(\text{O})_2(\text{CR}'\text{R}')_r\text{R}^{6b}$ ,  $\text{C}_{1-6}$  haloalkyl,  $\text{C}_{2-8}$  alkenyl substituted with 0-3  $\text{R}'$ ,  $\text{C}_{2-8}$  alkynyl substituted with 0-3  $\text{R}'$ ,  $(\text{CR}'\text{R}')_r$ phenyl substituted with 0-3  $\text{R}^{6e}$ , and a  $(\text{CH}_2)_r$ -5-6 membered heterocyclic system containing 1-2 heteroatoms selected from N, O, and S, substituted with 0-2  $\text{R}^{6e}$ ;

alternatively, two  $\text{R}^6$  on adjacent atoms on  $\text{R}^1$  may join to form a cyclic acetal;

$\text{R}^{6a}$ , at each occurrence, is selected from H, methyl substituted with 0-1  $\text{R}^{6g}$ ,  $\text{C}_{2-6}$  alkyl substituted with 0-2  $\text{R}^{6e}$ ,  $\text{C}_{3-8}$  alkenyl substituted with 0-2  $\text{R}^{6e}$ ,  $\text{C}_{3-8}$  alkynyl substituted with 0-2  $\text{R}^{6e}$ , a  $(\text{CH}_2)_r$ - $\text{C}_{3-10}$  carbocyclic residue substituted with 0-5  $\text{R}^{6e}$ , and a  $(\text{CH}_2)_r$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2  $\text{R}^{6e}$ ;

$\text{R}^{6b}$ , at each occurrence, is selected from H,  $\text{C}_{1-6}$  alkyl substituted with 0-2  $\text{R}^{6e}$ ,  $\text{C}_{3-8}$  alkenyl substituted with 0-2  $\text{R}^{6e}$ ,  $\text{C}_{3-8}$  alkynyl substituted with 0-2  $\text{R}^{6e}$ , a  $(\text{CH}_2)_r$ - $\text{C}_{3-6}$  carbocyclic residue substituted with 0-3  $\text{R}^{6e}$ , and a  $(\text{CH}_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2  $\text{R}^{6e}$ ;

$\text{R}^{6d}$ , at each occurrence, is selected from  $\text{C}_{3-8}$  alkenyl substituted with 0-2  $\text{R}^{6e}$ ,  $\text{C}_{3-8}$  alkynyl substituted with 0-2  $\text{R}^{6e}$ , methyl,  $\text{CF}_3$ ,  $\text{C}_{2-6}$  alkyl substituted with 0-3  $\text{R}^{6e}$ ,  $\text{C}_{2-4}$  haloalkyl, a  $(\text{CH}_2)_r$ - $\text{C}_{3-10}$  carbocyclic residue substituted with 0-3  $\text{R}^{6e}$ , and a  $(\text{CH}_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $\text{R}^{6e}$ ;

PH7442 NP  
10/776828

$R^{6e}$ , at each occurrence, is selected from  $C_{1-6}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl,  $(CH_2)_r C_{3-6}$  cycloalkyl, Cl, F, Br, I, CN,  $NO_2$ ,  $(CF_2)_r CF_3$ ,  $(CH_2)_r OC_{1-5}$  alkyl, OH, SH,  $(CH_2)_r SC_{1-5}$  alkyl,  $(CH_2)_r NR^{6f} R^{6f}$ , and  $(CH_2)_r$ phenyl;

$R^{6f}$ , at each occurrence, is selected from H,  $C_{1-5}$  alkyl, and  $C_{3-6}$  cycloalkyl, and phenyl;

$R^{6g}$  is independently selected from  $-C(O)R^{6b}$ ,  $-C(O)OR^{6d}$ ,  $-C(O)NR^{6f} R^{6f}$ , and  $(CH_2)_r$ phenyl;

$R^7$ , at each occurrence, is selected from  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl,  $(CH_2)_r C_{3-6}$  cycloalkyl, Cl, Br, I, F,  $NO_2$ , CN,  $(CR'R')_r NR^{7a} R^{7a}$ ,  $(CR'R')_r OH$ ,  $(CR'R')_r O(CR'R')_r R^{7d}$ ,  $(CR'R')_r SH$ ,  $(CR'R')_r C(O)H$ ,  $(CR'R')_r S(CR'R')_r R^{7d}$ ,  $(CR'R')_r C(O)OH$ ,  $(CR'R')_r C(O)(CR'R')_r R^{7b}$ ,  $(CR'R')_r C(O)NR^{7a} R^{7a}$ ,  $(CR'R')_r NR^{7f} C(O)(CR'R')_r R^{7b}$ ,  $(CR'R')_r C(O)O(CR'R')_r R^{7d}$ ,  $(CR'R')_r OC(O)(CR'R')_r R^{7b}$ ,  $(CR'R')_r OC(O)NR^{7a}(CR'R')_r R^{7a}$ ,  $(CR'R')_r NR^{7a} C(O)NR^{7a}(CR'R')_r R^{7a}$ ,  $(CR'R')_r NR^{7f} C(O)O(CR'R')_r R^{7d}$ ,  $(CR'R')_r C(=NR^{7f})NR^{7a} R^{7a}$ ,  $(CR'R')_r NHC(=NR^{7f})NR^{7f} R^{7f}$ ,  $(CR'R')_r S(O)_p(CR'R')_r R^{7b}$ ,  $(CR'R')_r S(O)_2 NR^{7a} R^{7a}$ ,  $(CR'R')_r NR^{7a} S(O)_2 NR^{7a} R^{7a}$ ,  $(CR'R')_r NR^{7f} S(O)_2(CR'R')_r R^{7b}$ ,  $C_{1-6}$  haloalkyl,  $C_{2-8}$  alkenyl substituted with 0-3  $R'$ ,  $C_{2-8}$  alkynyl substituted with 0-3  $R'$ , and  $(CR'R')_r$ phenyl substituted with 0-3  $R^{7e}$ ;

alternatively, two  $R^7$  on adjacent atoms on  $R^2$  may join to form a cyclic acetal;

PH7442 NP  
10/776828

- $R^{7a}$ , at each occurrence, is independently selected from H, methyl substituted with 0-1  $R^{7g}$ ,  $C_{2-6}$  alkyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkenyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkynyl substituted with 0-2  $R^{7e}$ , a  $(CH_2)_r$ - $C_{3-10}$  carbocyclic residue substituted with 0-5  $R^{7e}$ , and a  $(CH_2)_r$ -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2  $R^{7e}$ ;
- $R^{7b}$ , at each occurrence, is selected from  $C_{1-6}$  alkyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkenyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkynyl substituted with 0-2  $R^{7e}$ , a  $(CH_2)_r$ - $C_{3-6}$  carbocyclic residue substituted with 0-3  $R^{7e}$ , and a  $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2  $R^{7e}$ ;
- $R^{7d}$ , at each occurrence, is selected from  $C_{3-8}$  alkenyl substituted with 0-2  $R^{7e}$ ,  $C_{3-8}$  alkynyl substituted with 0-2  $R^{7e}$ , methyl,  $CF_3$ ,  $C_{2-4}$  haloalkyl,  $C_{2-6}$  alkyl substituted with 0-3  $R^{7e}$ , a  $(CH_2)_r$ - $C_{3-10}$  carbocyclic residue substituted with 0-3  $R^{7e}$ , and a  $(CH_2)_r$ -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $R^{7e}$ ;
- $R^{7e}$ , at each occurrence, is selected from  $C_{1-6}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl,  $(CH_2)_r$ - $C_{3-6}$  cycloalkyl, Cl, F, Br, I, CN,  $NO_2$ ,  $(CF_2)_r$ - $CF_3$ ,  $(CH_2)_r$ - $OC_{1-5}$  alkyl, OH, SH,  $C(O)OC_{1-5}$  alkyl,  $(CH_2)_r$ - $SC_{1-5}$  alkyl,  $(CH_2)_r$ - $NR^{7f}R^{7f}$ , and  $(CH_2)_r$ -phenyl;
- $R^{7f}$ , at each occurrence, is selected from H,  $C_{1-5}$  alkyl, and  $C_{3-6}$  cycloalkyl, and phenyl;

PH7442 NP  
10/776828

R<sup>7g</sup> is independently selected from -C(O)R<sup>7b</sup>, -C(O)OR<sup>7d</sup>,  
-C(O)NR<sup>7f</sup>R<sup>7f</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl;

R', at each occurrence, is selected from H, C<sub>1-6</sub> alkyl substituted  
with R<sup>6e</sup>, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>C<sub>3-6</sub> cycloalkyl,  
and (CH<sub>2</sub>)<sub>r</sub>phenyl substituted with R<sup>6e</sup>;

~~R<sup>8</sup> is selected from H, C<sub>1-4</sub> alkyl, and C<sub>3-4</sub> cycloalkyl;~~

R<sup>9</sup> is selected from H, C<sub>1-4</sub> alkyl, C<sub>3-4</sub> cycloalkyl, -C(O)H, and -  
C(O)-C<sub>1-4</sub>alkyl;

R<sup>10</sup> is independently selected from H, and C<sub>1-4</sub>alkyl substituted  
with 0-1 R<sup>10b</sup>;

R<sup>10b</sup>, at each occurrence, is independently selected from -OH, -SH,  
-NR<sup>10c</sup>R<sup>10c</sup>, -C(O)NR<sup>10c</sup>R<sup>10c</sup>, and -NHC(O)R<sup>10c</sup>;

R<sup>10c</sup> is selected from H, C<sub>1-4</sub> alkyl and C<sub>3-6</sub> cycloalkyl;

R<sup>11</sup> is selected from H, C<sub>1-4</sub> alkyl, (CHR)<sub>q</sub>OH, (CHR)<sub>q</sub>SH, (CHR)<sub>q</sub>OR<sup>11d</sup>,  
(CHR)<sub>q</sub>S(O)<sub>p</sub>R<sup>11d</sup>, (CHR)<sub>r</sub>C(O)R<sup>11b</sup>, (CHR)<sub>r</sub>NR<sup>11a</sup>R<sup>11a</sup>,  
(CHR)<sub>r</sub>C(O)NR<sup>11a</sup>R<sup>11a</sup>, (CHR)<sub>r</sub>C(O)NR<sup>11a</sup>OR<sup>11d</sup>, (CHR)<sub>q</sub>NR<sup>11a</sup>C(O)R<sup>11b</sup>,  
(CHR)<sub>q</sub>NR<sup>11a</sup>C(O)OR<sup>11d</sup>, (CHR)<sub>q</sub>OC(O)NR<sup>11a</sup>R<sup>11a</sup>, (CHR)<sub>r</sub>C(O)OR<sup>11d</sup>, a  
(CHR)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-5 R<sup>11e</sup>, and  
a (CHR)<sub>r</sub>-5-10 membered heterocyclic system containing 1-4  
heteroatoms selected from N, O, and S, substituted with 0-3  
R<sup>11e</sup>;

R<sup>11a</sup>, at each occurrence, is independently selected from H, C<sub>1-4</sub>  
alkyl, C<sub>3-4</sub> alkenyl, C<sub>3-4</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>C<sub>3-6</sub> cycloalkyl, a

PH7442 NP  
10/776828

$(\text{CH}_2)_r\text{-C}_{3-6}$  carbocyclic residue substituted with 0-5  $\text{R}^{11e}$ , and a  $(\text{CH}_2)_r\text{-5-6}$  membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $\text{R}^{11e}$ ;

$\text{R}^{11b}$ , at each occurrence, is independently selected from  $\text{C}_{1-4}$  alkyl,  $\text{C}_{2-4}$  alkenyl,  $\text{C}_{2-4}$  alkynyl, a  $(\text{CH}_2)_r\text{-C}_{3-6}$  carbocyclic residue substituted with 0-2  $\text{R}^{11e}$ , and a  $(\text{CH}_2)_r\text{-5-6}$  membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $\text{R}^{11e}$ ;

$\text{R}^{11d}$ , at each occurrence, is independently selected from H, methyl,  $-\text{CF}_3$ ,  $\text{C}_{2-4}$  alkyl,  $\text{C}_{3-6}$  alkenyl,  $\text{C}_{3-6}$  alkynyl, a  $\text{C}_{3-6}$  carbocyclic residue substituted with 0-3  $\text{R}^{11e}$ , and a  $(\text{CH}_2)_r\text{-5-6}$  membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $\text{R}^{11e}$ ;

$\text{R}^{11e}$ , at each occurrence, is selected from  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-8}$  alkenyl,  $\text{C}_{2-8}$  alkynyl,  $\text{C}_{3-6}$  cycloalkyl, Cl, F, Br, I, CN,  $\text{NO}_2$ ,  $(\text{CF}_2)_r\text{CF}_3$ ,  $(\text{CH}_2)_r\text{OC}_{1-5}$  alkyl, OH,  $-\text{O}-\text{C}_{1-6}$  alkyl, SH,  $(\text{CH}_2)_r\text{SC}_{1-5}$  alkyl,  $(\text{CH}_2)_r\text{NR}^{11f}\text{R}^{11f}$ , and  $(\text{CH}_2)_r\text{phenyl}$ ;

$\text{R}^{11f}$ , at each occurrence, is selected from H,  $\text{C}_{1-6}$  alkyl, and  $\text{C}_{3-6}$  cycloalkyl;

$\text{R}^{12}$  is selected from H,  $\text{C}_{1-4}$  alkyl,  $(\text{CHR})_q\text{OH}$ ,  $(\text{CHR})_q\text{SH}$ ,  $(\text{CHR})_q\text{OR}^{12d}$ ,  $(\text{CHR})_q\text{S}(\text{O})_p\text{R}^{12d}$ ,  $(\text{CHR})_r\text{C}(\text{O})\text{R}^{12b}$ ,  $(\text{CHR})_r\text{NR}^{12a}\text{R}^{12a}$ ,  $(\text{CHR})_r\text{C}(\text{O})\text{NR}^{12a}\text{OR}^{12d}$ ,  $(\text{CHR})_q\text{NR}^{12a}\text{C}(\text{O})\text{R}^{12b}$ ,  $(\text{CHR})_q\text{NR}^{12a}\text{C}(\text{O})\text{OR}^{12d}$ ,  $(\text{CHR})_q\text{OC}(\text{O})\text{NR}^{12a}\text{R}^{12a}$ ,  $(\text{CHR})_r\text{C}(\text{O})\text{OR}^{12d}$ , a



PH7442 NP  
10/776828

(CHR)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-5 R<sup>12e</sup>, and a (CHR)<sub>r</sub>-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>12e</sup>;

R<sup>12a</sup>, at each occurrence, is independently selected from H, C<sub>1-4</sub> alkyl, C<sub>3-4</sub> alkenyl, C<sub>3-4</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> cycloalkyl, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-5 R<sup>12e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>12e</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-6</sub> carbocyclic residue substituted with 0-2 R<sup>12e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>12e</sup>;

R<sup>12d</sup>, at each occurrence, is independently selected from H, methyl, -CF<sub>3</sub>, C<sub>2-4</sub> alkyl, C<sub>3-6</sub> alkenyl, C<sub>3-6</sub> alkynyl, a C<sub>3-6</sub> carbocyclic residue substituted with 0-3 R<sup>12e</sup>, and a (CH<sub>2</sub>)<sub>r</sub>-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>12e</sup>;

R<sup>12e</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>, (CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>r</sub>OC<sub>1-5</sub> alkyl, OH, -O-C<sub>1-6</sub> alkyl, SH, (CH<sub>2</sub>)<sub>r</sub>SC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>NR<sup>12f</sup>R<sup>12f</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl;

PH7442 NP  
10/776828

$R^{12f}$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, and  $C_{3-6}$  cycloalkyl;

$R^{13}$ , at each occurrence, is independently selected from H, and  $C_{1-4}$  alkyl substituted with 0-1  $R^{13b}$ , -OH, -NH<sub>2</sub>, F, Cl, Br, I, -OR<sup>13a</sup>, -N(R<sup>13a</sup>)<sub>2</sub>, and  $C_{1-4}$  alkyl substituted with 0-3  $R^{13b}$ ;

$R^{13a}$  is selected from H,  $C_{1-4}$  alkyl and  $C_{3-6}$  cycloalkyl;

$R^{13b}$ , at each occurrence, is independently selected from -OH, -SH, -NR<sup>13c</sup>R<sup>13c</sup>, -C(O)NR<sup>13c</sup>R<sup>13c</sup>, and -NHC(O)R<sup>13c</sup>;

$R^{13c}$  is selected from H,  $C_{1-4}$  alkyl and  $C_{3-6}$  cycloalkyl;

~~$R^{14}$ , at each occurrence, is independently selected from H and  $C_{1-4}$  alkyl,~~

~~alternatively, two  $R^{14}$ s, along with the carbon atom to which they are attached, join to form a  $C_{3-6}$  carbocyclic ring,~~

~~$R^{15}$ , at each occurrence, is independently selected from H,  $C_{1-4}$  alkyl, OH, NH<sub>2</sub>, O  $C_{1-4}$  alkyl, NR<sup>15a</sup>R<sup>15a</sup>, C(O)NR<sup>15a</sup>R<sup>15a</sup>, NR<sup>15a</sup>C(O)R<sup>15b</sup>, NR<sup>15a</sup>C(O)OR<sup>15d</sup>, OC(O)NR<sup>15a</sup>R<sup>15a</sup>, and (CHR)<sub>2</sub>C(O)OR<sup>15d</sup>,~~

~~alternatively, two  $R^{15}$ s, along with the carbon atom or atoms to which they are attached, join to form a  $C_{3-6}$  carbocyclic ring,~~

~~R<sup>15a</sup>, at each occurrence, is independently selected~~

~~C<sub>1-4</sub>-alkyl,~~

~~R<sup>15b</sup>, at each occurrence, is independently selected from C<sub>1-4</sub>~~

~~alkyl, C<sub>3-6</sub>-alkenyl, and C<sub>3-6</sub>-alkynyl,~~

~~R<sup>15d</sup>, at each occurrence, is independently selected from C<sub>1-4</sub>~~

~~alkyl, C<sub>3-6</sub>-alkenyl, and C<sub>3-6</sub>-alkynyl,~~

~~R<sup>16</sup> is selected from C<sub>1-4</sub>-alkyl,~~

l is selected from 1, 2 and 3;

n is 1; ~~selected from 0, 1, 2, and 3,~~

m is selected from 0 and 1;

p, at each occurrence, is independently selected from 0, 1, and 2;

q, at each occurrence, is independently selected from 1, 2, 3, and  
4;

r, at each occurrence, is independently selected from 0, 1, 2, 3,  
and 4;

t, at each occurrence, is independently selected from 2, 3, and 4;

s is selected from 0 and 1.


3. (ORIGINAL) The compound of claim 2, wherein

m is 0.

PH7442 NP  
10/776828

4. (CURRENTLY AMENDED) The compound of claim 3, wherein:

ring B is ~~selected from~~



substituted with 0-1  $R^5$ ; and

$R^{11}$  and  $R^{12}$  are H.

5. The compounds of claim 4, wherein:

R<sup>5</sup>, at each occurrence, is independently selected from H, C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CRR)<sub>r</sub>OH, (CRR)<sub>r</sub>SH, (CRR)<sub>r</sub>OR<sup>5d</sup>, (CRR)<sub>r</sub>SR<sup>5d</sup>, (CRR)<sub>r</sub>NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>r</sub>C(O)OH, (CRR)<sub>r</sub>C(O)R<sup>5b</sup>, (CRR)<sub>r</sub>C(O)NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>r</sub>NR<sup>5a</sup>C(O)R<sup>5b</sup>, (CRR)<sub>r</sub>NR<sup>5a</sup>C(O)OR<sup>5d</sup>, (CRR)<sub>r</sub>OC(O)NR<sup>5a</sup>R<sup>5a</sup>, (CHR)<sub>r</sub>NR<sup>5a</sup>C(O)NR<sup>5a</sup>R<sup>5a</sup>, CRR(CRR)<sub>r</sub>NR<sup>5a</sup>C(O)H, (CRR)<sub>r</sub>C(O)OR<sup>5b</sup>, (CRR)<sub>r</sub>OC(O)R<sup>5b</sup>, (CRR)<sub>r</sub>S(O)<sub>p</sub>R<sup>5b</sup>, (CRR)<sub>r</sub>S(O)<sub>2</sub>NR<sup>5a</sup>R<sup>5a</sup>, (CRR)<sub>r</sub>NR<sup>5a</sup>S(O)<sub>2</sub>R<sup>5b</sup>, and C<sub>1-6</sub> haloalkyl;

R<sup>5a</sup>, at each occurrence, is independently selected from H, methyl, C<sub>1-6</sub> alkyl substituted with 0-2 R<sup>5e</sup> wherein the alkyl is selected from ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, hexyl, C<sub>3</sub> alkenyl substituted with 0-1 R<sup>5e</sup>, wherein

PH7442 NP  
10/776828

the alkenyl is selected from allyl, C<sub>3</sub> alkynyl substituted with 0-1 R<sup>5e</sup> wherein the alkynyl is selected from propynyl, and a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-4</sub> carbocyclic residue substituted with 0-5 R<sup>5e</sup>, wherein the carbocyclic residue is selected from cyclopropyl, and cyclobutyl;

R<sup>5b</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl substituted with 0-2 R<sup>5e</sup>, wherein the alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, and hexyl, a (CH<sub>2</sub>)<sub>r</sub>-C<sub>3-4</sub> carbocyclic residue substituted with 0-2 R<sup>5e</sup>, wherein the carbocyclic residue is selected from cyclopropyl, and cyclobutyl; and

R<sup>5d</sup>, at each occurrence, is selected from methyl, CF<sub>3</sub>, C<sub>2-6</sub> alkyl substituted with 0-2 R<sup>5e</sup>, wherein the alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, and hexyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, and a C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>5e</sup>.

6. (CURRENTLY AMENDED) The compound of claim 5, wherein:

~~R<sup>4</sup> is selected from H, C<sub>1-6</sub> alkyl, C<sub>3-8</sub> alkenyl, C<sub>3-8</sub> alkynyl, (CRR)<sub>e</sub>OH, (CRR)<sub>e</sub>SH, (CRR)<sub>e</sub>OR<sup>4d</sup>, (CRR)<sub>e</sub>SR<sup>4d</sup>, (CRR)<sub>e</sub>NR<sup>4a</sup>R<sup>4a</sup>, (CRR)<sub>e</sub>C(O)OH, (CRR)<sub>e</sub>C(O)R<sup>4b</sup>, (CRR)<sub>e</sub>C(O)NR<sup>4a</sup>R<sup>4a</sup>, (CRR)<sub>e</sub>NR<sup>4a</sup>C(O)R<sup>4b</sup>, (CRR)<sub>e</sub>OC(O)NR<sup>4a</sup>R<sup>4a</sup>, (CRR)<sub>e</sub>NR<sup>4a</sup>C(O)OR<sup>4d</sup>, (CRR)<sub>e</sub>NR<sup>4a</sup>C(O)R<sup>4b</sup>, (CRR)<sub>e</sub>C(O)OR<sup>4b</sup>, (CRR)<sub>e</sub>OC(O)R<sup>4b</sup>, (CRR)<sub>e</sub>S(O)<sub>2</sub>R<sup>4b</sup>, (CRR)<sub>e</sub>S(O)<sub>2</sub>NR<sup>4a</sup>R<sup>4a</sup>, (CRR)<sub>e</sub>NR<sup>4a</sup>S(O)<sub>2</sub>R<sup>4b</sup>~~

R, at each occurrence, is independently selected from H, methyl, ethyl, propyl, allyl, propynyl, (CH<sub>2</sub>)<sub>r</sub>C<sub>3-6</sub> cycloalkyl, and (CH<sub>2</sub>)<sub>r</sub>phenyl substituted with R<sup>6e</sup>;

PH7442 NP  
10/776828

R<sup>5</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, allyl, propynyl, (CH<sub>2</sub>)<sub>r</sub>OH, (CH<sub>2</sub>)<sub>r</sub>OR<sup>5d</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5a</sup>R<sup>5a</sup>, (CH<sub>2</sub>)<sub>r</sub>C(O)OH, (CH<sub>2</sub>)<sub>r</sub>C(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>C(O)NR<sup>5a</sup>R<sup>5a</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5a</sup>C(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>OC(O)NR<sup>5a</sup>R<sup>5a</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5a</sup>C(O)OR<sup>5d</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5a</sup>C(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>C(O)OR<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>OC(O)R<sup>5b</sup>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>5a</sup>S(O)<sub>2</sub>R<sup>5b</sup>, and C<sub>1-6</sub> haloalkyl;

R<sup>5a</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, hexyl, cyclopropyl, and cyclobutyl; and

r, at each occurrence, is selected from 0, 1, and 2.

7. (CURRENTLY AMENDED) The compound of claim 6, wherein:

R<sup>1</sup> is selected from phenyl substituted with 0-2 R<sup>6</sup>, naphthyl substituted with 0-2 R<sup>6</sup>, and ~~a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R<sup>6</sup> wherein the heteroaryl is selected from indolyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benzo[b]thiophene, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalenyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrido[2,3-d]pyrimidinyl, pyrimido[5,4-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrole[2,1-f][1,2,4]triazine, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl;~~

PH7442 NP  
10/776828

$R^2$  is selected from ~~phenyl substituted with 0-2  $R^7$~~ , and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3  $R^7$  wherein the heteroaryl is selected from indolyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benzo[b]thiophene, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrido[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,1-f][1,2,4]triazine, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl.

$R^4$  is selected from ~~H, methyl, ethyl, propyl, i propyl, butyl, i butyl, allyl, propynyl,  $(CRR)_e OH$ ,  $(CRR)_e SH$ ,  $(CRR)_e OR^{4d}$ ,  $(CRR)_e SR^{4d}$ ,  $(CRR)_e NR^{4a}R^{4a}$ ,  $(CRR)_e C(O)OH$ ,  $(CRR)_e C(O)R^{4b}$ ,  $(CRR)_e C(O)NR^{4a}R^{4a}$ ,  $(CRR)_e NR^{4a}C(O)R^{4b}$ ,  $(CRR)_e OC(O)NR^{4a}R^{4a}$ ,  $(CRR)_e NR^{4a}C(O)OR^{4d}$ ,  $(CRR)_e NR^{4a}C(O)R^{4b}$ ,  $(CRR)_e C(O)OR^{4b}$ ,  $(CRR)_e OC(O)R^{4b}$ ,  $(CRR)_e S(O)_2R^{4b}$ ,  $(CRR)_e S(O)_2NR^{4a}R^{4a}$ ,  $(CRR)_e NR^{4a}S(O)_2R^{4b}$~~ .

$R^{4a}$ , at each occurrence, is independently selected from ~~H, methyl substituted with 0-1  $R^{4e}$ ,  $C_{2-6}$ -alkyl substituted with 0-3  $R^{4e}$  wherein  $C_{2-6}$  is selected from ethyl, propyl, i propyl, butyl, i butyl, t butyl, pentyl and hexyl, and a  $(CH_2)_2-C_{3-6}$  carbocyclic residue substituted with 0-4  $R^{4e}$  wherein the carbocyclic residue is selected from cyclopropyl, cyclohexyl, and phenyl~~.

PH7442 NP  
10/776828

~~R<sup>4b</sup> is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, and cyclopropyl.~~

~~R<sup>4d</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, and cyclopropyl, and~~

~~R<sup>5</sup> is selected from H, methyl, ethyl, propyl, i-propyl, and cyclopropyl.~~

8. (ORIGINAL) The compound of claim 7, wherein:

R<sup>6</sup>, at each occurrence, is selected from C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CR'R')<sub>r</sub>C<sub>3-6</sub> cycloalkyl, Cl, Br, I, F, NO<sub>2</sub>, CN, (CR'R')<sub>r</sub>NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>r</sub>OH, (CR'R')<sub>r</sub>O(CR'R')<sub>r</sub>R<sup>6d</sup>, (CR'R')<sub>r</sub>SH, (CR'R')<sub>r</sub>C(O)H, (CR'R')<sub>r</sub>S(CR'R')<sub>r</sub>R<sup>6d</sup>, (CR'R')<sub>r</sub>C(O)OH, (CR'R')<sub>r</sub>C(O)(CR'R')<sub>r</sub>R<sup>6b</sup>, (CR'R')<sub>r</sub>C(O)NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>r</sub>NR<sup>6f</sup>C(O)(CR'R')<sub>r</sub>R<sup>6b</sup>, (CR'R')<sub>r</sub>C(O)O(CR'R')<sub>r</sub>R<sup>6d</sup>, (CR'R')<sub>r</sub>NR<sup>6a</sup>C(O)NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>r</sub>NR<sup>6a</sup>C(S)NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>r</sub>OC(O)(CR'R')<sub>r</sub>R<sup>6b</sup>, (CR'R')<sub>r</sub>S(O)<sub>p</sub>(CR'R')<sub>r</sub>R<sup>6b</sup>, (CR'R')<sub>r</sub>S(O)<sub>2</sub>NR<sup>6a</sup>R<sup>6a</sup>, (CR'R')<sub>r</sub>NR<sup>6f</sup>S(O)<sub>2</sub>(CR'R')<sub>r</sub>R<sup>6b</sup>, (CR'R')<sub>r</sub>NR<sup>6f</sup>S(O)<sub>2</sub>NR<sup>6a</sup>R<sup>6a</sup>, C<sub>1-6</sub> haloalkyl, and (CR'R')<sub>r</sub>phenyl substituted with 0-3 R<sup>6e</sup>, and a (CH<sub>2</sub>)<sub>r-5-6</sub> membered heterocyclic system containing 1-2 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>6e</sup>;

R<sup>6a</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl and phenyl;

R<sup>6b</sup>, at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;



PH7442 NP  
10/776828

R<sup>6d</sup>, at each occurrence, is selected from methyl, CF<sub>3</sub>, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;

R<sup>6e</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>, (CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>r</sub>OC<sub>1-5</sub> alkyl, OH, SH, (CH<sub>2</sub>)<sub>r</sub>SC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>NR<sup>6f</sup>R<sup>6f</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl;

R<sup>6f</sup>, at each occurrence, is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;

R<sup>7</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, pentyl, hexyl, (CR'R')<sub>r</sub>C<sub>3-6</sub> cycloalkyl, Cl, Br, I, F, NO<sub>2</sub>, CN, (CR'R')<sub>r</sub>NR<sup>7a</sup>R<sup>7a</sup>, (CR'R')<sub>r</sub>OH, (CR'R')<sub>r</sub>O(CH)<sub>r</sub>R<sup>7d</sup>, (CR'R')<sub>r</sub>SH, (CR'R')<sub>r</sub>C(O)H, (CR'R')<sub>r</sub>S(CR'R')<sub>r</sub>R<sup>7d</sup>, (CR'R')<sub>r</sub>C(O)OH, (CR'R')<sub>r</sub>C(O)(CR'R')<sub>r</sub>R<sup>7b</sup>, (CR'R')<sub>r</sub>C(O)NR<sup>7a</sup>R<sup>7a</sup>, (CR'R')<sub>r</sub>NR<sup>7f</sup>C(O)(CR'R')<sub>r</sub>R<sup>7b</sup>, (CR'R')<sub>r</sub>C(O)O(CR'R')<sub>r</sub>R<sup>7d</sup>, (CR'R')<sub>r</sub>OC(O)(CR'R')<sub>r</sub>R<sup>7b</sup>, (CR'R')<sub>r</sub>NR<sup>7a</sup>C(O)NR<sup>7a</sup>R<sup>7a</sup>, (CR'R')<sub>r</sub>NR<sup>7a</sup>C(O)O(CR'R')<sub>r</sub>R<sup>7d</sup>, (CR'R')<sub>r</sub>S(O)<sub>p</sub>(CR'R')<sub>r</sub>R<sup>7b</sup>, (CR'R')<sub>r</sub>S(O)<sub>2</sub>NR<sup>7a</sup>R<sup>7a</sup>, (CR'R')<sub>r</sub>NR<sup>7f</sup>S(O)<sub>2</sub>(CR'R')<sub>r</sub>R<sup>7b</sup>, C<sub>1-6</sub> haloalkyl, and (CR'R')<sub>r</sub>phenyl substituted with 0-3 R<sup>7e</sup>;

R<sup>7a</sup>, at each occurrence, is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl,, prop-2-enyl, 2-methyl-2-propenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, CH<sub>2</sub>cyclopropyl, and benzyl;

R<sup>7b</sup>, at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl,

PH7442 NP  
10/776828

cyclopropyl, cyclopentyl, CH<sub>2</sub>-cyclopentyl, cyclohexyl, CH<sub>2</sub>-cyclohexyl, CF<sub>3</sub>, pyrrolidinyl, morpholinyl, piperizenyl substituted with 0-1 R<sup>7e</sup>, and azetidiny;

R<sup>7d</sup>, at each occurrence, is selected from methyl, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, and cyclopropyl;


R<sup>7e</sup>, at each occurrence, is selected from C<sub>1-6</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, (CH<sub>2</sub>)<sub>r</sub>C<sub>3-6</sub> cycloalkyl, Cl, F, Br, I, CN, NO<sub>2</sub>, (CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>r</sub>OC<sub>1-5</sub> alkyl, OH, SH, C(O)OC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>SC<sub>1-5</sub> alkyl, (CH<sub>2</sub>)<sub>r</sub>NR<sup>7f</sup>R<sup>7f</sup>, and (CH<sub>2</sub>)<sub>r</sub>phenyl;

R<sup>7f</sup>, at each occurrence, is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl; and

r is 0 or 1.

9. (ORIGINAL) The compound of claim 8, wherein:

R<sup>7</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, pentyl, hexyl, Cl, Br, I, F, CN, NO<sub>2</sub>, NR<sup>7a</sup>R<sup>7a</sup>, NHC(O)NHR<sup>7a</sup>, NR<sup>7a</sup>C(O)R<sup>7b</sup>, NR<sup>7a</sup>C(O)OR<sup>7d</sup>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, OCF<sub>3</sub>, C(O)R<sup>7b</sup>, C(O)OR<sup>7d</sup>, NR<sup>7f</sup>C(O)NR<sup>7a</sup>R<sup>7a</sup>, NHS(O)<sub>2</sub>R<sup>7b</sup>,

PH7442 NP  
10/776828

10. (CURRENTLY AMENDED) The compound of claim 9, wherein:

ring B is selected from and

and ring B being optionally substituted with 0-1  $R^5$ ;

~~Z is selected from a bond,  $NR^8C(O)-$ ,  $C(O)NH-$ , and  $NHC(O)NH-$ ,~~

$R^1$  is selected from a C<sub>6-10</sub> aryl group substituted with 0-3  $R^6$  wherein the aryl group is selected from phenyl and naphthyl, and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N and O, substituted with 0-3  $R^6$  wherein the heteroaryl system is selected from indolyl, pyridinyl, pyrimidinyl, pyrido[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, imidazolyl, and pyrrolyl  $R^2$  is phenyl substituted with 0-2  $R^7$ ;

PH7442 NP  
10/776828

~~R<sup>4</sup> is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, and (CH<sub>2</sub>)<sub>r</sub> C(O)R<sup>4b</sup>;~~

R<sup>5</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, F, Cl, Br, I, NO<sub>2</sub>, CN, O(CH<sub>2</sub>)<sub>r</sub>R<sup>6d</sup>, C(O)H, C(O)R<sup>6d</sup>, C(O)OH, SR<sup>6d</sup>, NR<sup>6a</sup>R<sup>6a</sup>, NC(O)R<sup>6b</sup>, OC(O)R<sup>6b</sup>, S(O)<sub>p</sub>R<sup>6b</sup>, (CHR')<sub>r</sub>S(O)<sub>2</sub>NR<sup>6a</sup>R<sup>6a</sup>, and CF<sub>3</sub>;


R<sup>6a</sup> is H, methyl, or ethyl;

R<sup>6b</sup> is H, methyl, ethyl, propyl, i-propyl or butyl;

R<sup>6d</sup> is methyl, phenyl, CF<sub>3</sub>, and (CH<sub>2</sub>)-phenyl; and

r is 0 or 1.

11. (CURRENTLY AMENDED) The compound of claim 10, wherein:

ring B is , and ring B being substituted with 0-1 R<sup>5</sup>;

R<sup>1</sup> is selected from a C<sub>6-10</sub> aryl group substituted with 0-3 R<sup>6</sup> wherein the aryl group is selected from phenyl, ~~and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N and O, substituted with 0-3 R<sup>6</sup> wherein the heteroaryl system is selected from indolyl and pyridinyl;~~

R<sup>4</sup> is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, allyl and (CH<sub>2</sub>)<sub>r</sub> C(O)R<sup>4b</sup>;

PH7442 NP  
10/776828

R<sup>5</sup> is selected from H, OH, OCH<sub>3</sub>, and NR<sup>5a</sup>R<sup>5a</sup>;


R<sup>5a</sup> is selected from H, methyl, ethyl, propyl, i-propyl, butyl, s-butyl, i-butyl, t-butyl, pentyl, hexyl, allyl, propargyl, cyclopropyl, cyclopropylmethyl, acetyl, methysulfonyl, -C(O)CF<sub>3</sub>, C(=N)NH<sub>2</sub>, benzyl, and -C(O)O-t-butyl;

R<sup>6</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, vinyl, F, Cl, Br, I, CN, NR<sup>6a</sup>R<sup>6a</sup>, C(O)H, C(O)OH, C(O)R<sup>6b</sup>, SR<sup>6d</sup>, S(O)<sub>p</sub>R<sup>6d</sup>, S(O)<sub>2</sub>NR<sup>6a</sup>R<sup>6a</sup>, CF<sub>3</sub>, and CH<sub>2</sub>OH;

R<sup>6b</sup> is H, methyl, ethyl, propyl, i-propyl or butyl;

R<sup>6d</sup> is methyl;

R<sup>7</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, pentyl, hexyl, Cl, Br, I, F, CN, NO<sub>2</sub>, NR<sup>7a</sup>R<sup>7a</sup>, NHC(O)NHR<sup>7a</sup>, NR<sup>7a</sup>C(O)R<sup>7b</sup>, NR<sup>7a</sup>C(O)OR<sup>7d</sup>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, OCF<sub>3</sub>, OCF<sub>2</sub>CF<sub>3</sub>, OCHF<sub>2</sub>, and OCH<sub>2</sub>F, C(O)OR<sup>7d</sup>, C(O)R<sup>7b</sup>, NR<sup>7c</sup>C(O)NR<sup>7a</sup>R<sup>7a</sup>, NHS(O)<sub>2</sub>R<sup>7b</sup>,


PH7442 NP  
10/776828

$R^{7a}$  is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, neo-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

$R^{7b}$  is selected from cyclohexyl and  $CF_3$ ; and

$R^{7d}$  is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl.

12. (ORIGINAL) The compound of claim 11, wherein:

ring B is selected from , ring B being substituted with 0-1  $R^5$ ;

$R^1$  is selected from a  $C_{6-10}$  aryl group substituted with 0-3  $R^6$  wherein the aryl group is phenyl;

PH7442 NP  
10/776828

R<sup>6</sup> is selected from methyl, ethyl, propyl, i-propyl, F, Cl, Br, CN, SCH<sub>3</sub>, and CF<sub>3</sub>;


R<sup>7</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, pentyl, hexyl, phenyl, adamantyl, benzyl, Cl, Br, I, F, CN, NO<sub>2</sub>, NR<sup>7a</sup>R<sup>7a</sup>, OR<sup>7d</sup>, NHC(O)NHR<sup>7a</sup>, NR<sup>7a</sup>C(O)R<sup>7b</sup>, NR<sup>7a</sup>C(O)OR<sup>7d</sup>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, OCF<sub>3</sub>, OCF<sub>2</sub>CF<sub>3</sub>, OCHF<sub>2</sub>, and OCH<sub>2</sub>F, C(O)OR<sup>7d</sup>, C(O)R<sup>7b</sup>, and NR<sup>7f</sup>C(O)NR<sup>7a</sup>R<sup>7a</sup>;

R<sup>7a</sup> is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, neo-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

13. (ORIGINAL) The compound of claim 12, wherein

E is selected from -CH<sub>2</sub>-NH-, -C(O)-NH- and -SO<sub>2</sub>-CH<sub>2</sub>-.

14. (ORIGINAL) The compound of claim 1, wherein

B is , ring B being substituted with 0-1 R<sup>5</sup>; and

R<sup>5</sup> is selected from H, N(→O)R<sup>5a</sup>R<sup>5a</sup>, N<sub>3</sub>, NR<sup>5a</sup>C(O)R<sup>5b</sup>, NR<sup>5a</sup>C(O)H, NR<sup>5a</sup>C(O)OR<sup>5d</sup>, NR<sup>5a</sup>C(O)NR<sup>5a</sup>R<sup>5a</sup>, and NR<sup>5a</sup>R<sup>5a</sup>, and a (CH<sub>2</sub>)<sub>r-5-6</sub> membered heterocyclic system containing 1-2 heteroatoms selected from N, O, and S, substituted with 0-2 R<sup>5e</sup>, wherein the heterocyclic system is selected from pyrrolidinyl, piperidinyl, pyrrolidin-2-one, and isothiazolidine 1,1-dioxide.

PH7442 NP  
10/776828

15. (CANCELED)

16. (ORIGINAL) The compound of claim 12, wherein

R<sup>6</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, vinyl, F, Cl, Br, I, C(O)H, C(O)R<sup>6b</sup>, SR<sup>6d</sup>, S(O)<sub>p</sub>R<sup>6d</sup>, CF<sub>3</sub>, and CH<sub>2</sub>OH;

R<sup>6b</sup> is H, methyl, ethyl, propyl, i-propyl or butyl;


R<sup>6d</sup> is methyl;

R<sup>7</sup> is selected from Cl, Br, NR<sup>7a</sup>R<sup>7a</sup>, NR<sup>7a</sup>C(O)OR<sup>7d</sup>, NHC(O)NHR<sup>7a</sup>, OCF<sub>3</sub>, and CF<sub>3</sub>;

R<sup>7a</sup> is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, neo-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;


R<sup>7d</sup> is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl.

17. (ORIGINAL) The compound of claim 1, wherein the compound is of formula (Ia) or (Ic)



(Ia)

or



41



PH7442 NP

10/776828

(Ic).

18. (CURRENTLY AMENDED) The compound of claim 1, wherein the compound is of formula (I) is selected:

~~2-[(3S)-1-[(1,2-cis)-2-(4-Methylsulfonyl-benzoylamino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl-carbamoyl]-4-trifluoromethyl-phenyl)-carbamic acid tert-butyl ester,~~

~~2-[(3S)-1-[(1,2-cis)-2-(4-Methylsulfonyl-benzoylamino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl-carbamoyl]-4-trifluoromethyl-phenyl)-amino,~~

~~N-[(3S)-1-[(1S,2R,4R)-(Isopropyl-methyl-amino)-2-(toluene-4-sulfonylmethyl)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide,~~

~~N-[(3S)-1-[(1S,2R,4S)-(Isopropyl-methyl-amino)-2-(toluene-4-sulfonylmethyl)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide,~~

~~N-[(3S)-1-[(1S,2R,4R)-2-Benzenesulfonylmethyl-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide,~~

~~N-[(3S)-1-[(1S,2R,4S)-2-Benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide,~~

PH7442 NP  
10/776828

~~N-((3S)-1-[(1S,2R,4R)-2-Benzenesulfonylmethyl-4-(isopropyl-ethyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl)-3-trifluoromethyl-benzamide,~~

~~N-((3S)-1-[(1S,2R,4S)-2-Benzenesulfonylmethyl-4-(isopropyl-ethyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl)-3-trifluoromethyl-benzamide,~~

~~N-((3S)-1-[(1S,2R,4R)-2-Benzenesulfonylmethyl-4-(isopropyl-cyclopropylmethyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl)-3-trifluoromethyl-benzamide,~~

~~(+)-N-((3S\*)-1-[(1S\*,2R\*,4R\*)-4-Azido-2-(4-methylsulfonyl-benzenesulfonylmethyl)-cyclohexyl]-3-methyl-2-oxo-pyrrolidin-3-yl)-3-trifluoromethyl-benzamide,~~

~~(+)-N-((3S\*)-1-[(1S\*,2R\*,4R\*)-4-Amino-2-(4-methylsulfonyl-benzenesulfonylmethyl)-cyclohexyl]-3-methyl-2-oxo-pyrrolidin-3-yl)-3-trifluoromethyl-benzamide,~~

~~(+)-N-((3S\*)-1-[(1S\*,2R\*,4R\*)-4-Isopropylamino-2-(4-methylsulfonyl-benzenesulfonylmethyl)-cyclohexyl]-3-methyl-2-oxo-pyrrolidin-3-yl)-3-trifluoromethyl-benzamide,~~

~~(+)-N-((3S\*)-1-[(1S\*,2R\*,4R\*)-4-(Isopropyl-methyl-amino)-2-(4-methylsulfonyl-benzenesulfonylmethyl)-cyclohexyl]-3-methyl-2-oxo-pyrrolidin-3-yl)-3-trifluoromethyl-benzamide,~~

~~(+)-N-((3S\*)-1-[(1S\*,2R\*,4R\*)-4-(Isopropyl-prop-2-ynyl-amino)-2-(4-methylsulfonyl-benzenesulfonylmethyl)-cyclohexyl]-3-methyl-2-oxo-pyrrolidin-3-yl)-3-trifluoromethyl-benzamide,~~

PH7442 NP

10/776828

~~(±) N-[(3S)-1-[(1S\*,2R\*,4R\*)-4-(Cyclopropylmethyl isopropyl-  
amino)-2-(4-methylsulfanyl-benzenesulfonylmethyl)-  
cyclohexyl]-3-methyl-2-oxo-pyrrolidin-3-yl]-3-  
trifluoromethyl-benzamide;~~

~~N-[(3S)-1-[4-(Isopropyl-methyl-amino)-2-(4-methylsulfanyl-  
benzenesulfonylmethyl)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-N-  
methyl-3-trifluoromethyl-benzamide;~~

~~N-[(3S)-1-[(1S,2R,4R)-4-(Isopropyl-methyl-amino)-2-(4-  
methylsulfanyl-benzenesulfonylmethyl)-cyclohexyl]-2-oxo-  
pyrrolidin-3-yl]-3-trifluoromethyl-benzamide;~~

~~1-[(3S)-1-[(1S,2R,4R)-4-(Isopropyl-methyl-amino)-2-(4-  
methylsulfanyl-benzenesulfonylmethyl)-cyclohexyl]-2-oxo-  
pyrrolidin-3-yl]-3-(3-trifluoromethyl-phenyl)-urea;~~

~~N-[(3S)-1-[(1S,2R,4R)-4-(Isopropyl-methyl-amino)-2-(4-  
methylsulfanyl-benzenesulfonylmethyl)-cyclohexyl]-2-oxo-  
pyrrolidin-3-yl]-3-trifluoromethyl-benzenesulfenamide;~~

~~N-[(3S)-1-[(1S,2R,4R)-4-(Isopropyl-methyl-amino)-2-(4-  
methylsulfanyl-benzenesulfonylmethyl)-cyclohexyl]-2-oxo-  
pyrrolidin-3-yl]-benzamide;~~

~~[(3S)-1-[(1S,2R,4R)-2-Benzenesulfonylmethyl-4-(isopropyl-methyl-  
amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-3-(3-  
trifluoromethyl-phenyl)-urea;~~

PH7442 NP  
10/776828

~~N-[(3S)-1-[(1S,2R,4R)-2-Benzenesulfonylmethyl-4-isopropylamino-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide,~~

~~N-[(3S)-1-[(1S,2R,4R)-4-(Allyl-isopropyl-amino)-2-benzenesulfonylmethyl-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide,~~

~~1-[(1S,2R)-2-Benzenesulfonylmethyl-4-isopropylamino-cyclohexyl]-2-oxo-pyrrolidine-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide,~~

~~1-[(1S,2R)-2-Benzenesulfonylmethyl-4-isopropylamino-cyclohexyl]-2-oxo-pyrrolidine-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide,~~

~~(2-[(3S)-1-[(1S,2R)-2-(4-Methylsulfonyl-benzylamino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl-carbamoyl]-4-trifluoromethyl-phenyl)-carbamie acid tert-butyl-ester,~~

~~N-[(3S)-1-[(1S,2R,4R)-2-Benzenesulfonylmethyl-4(R)-(isopropyl-propyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide,~~

~~(1)-1-[(1S\*,2R\*,4R\*)-4-Isopropylamino-2-(4-methylsulfonyl-benzenesulfonylmethyl)-cyclohexyl]-4-(3-trifluoromethyl-phenyl)-5,6-dihydro-1H-pyridin-2-one,~~

~~(1)-1-[(1S\*,2R\*,4R\*)-4-Isopropylamino-2-(4-benzenesulfonylmethyl)-cyclohexyl]-4-(3-trifluoromethyl-phenyl)-5,6-dihydro-1H-pyridin-2-one,~~

PH7442 NP  
10/776828

~~(1) 1 - [(1S\*, 2R\*, 4R\*) 4 Isopropylmethylamino 2 (4 methylsulfanyl-  
benzenesulfonylmethyl) cyclohexyl] 4 (3 trifluoromethyl-  
phenyl) 5,6 dihydro 1H pyridin 2 one,~~

~~(1) 1 - [(1S\*, 2R\*, 4R\*) 4 Amino 2 (4 methylsulfanyl-  
benzenesulfonylmethyl) cyclohexyl] 4 (3-  
trifluoromethoxyphenyl) 5,6 dihydro 1H pyridin 2 one,~~

~~(1) 1 - [(1S\*, 2R\*, 4R\*) 4 Isopropylamino 2 (4 methylsulfanyl-  
benzenesulfonylmethyl) cyclohexyl] 4 (3-  
trifluoromethoxyphenyl) 5,6 dihydro 1H pyridin 2 one,~~

~~(1) 1 - [(1S\*, 2R\*, 4R\*) 4 Isopropylamino 2 (4 benzenesulfonylmethyl)-  
cyclohexyl] 4 (3 trifluoromethyl phenyl) piperidin 2 one,~~

~~(S) 3 (3 (trifluoromethyl)benzylamino) 1 ((1S, 2R, 4R) 4-  
(isopropyl(methyl)amino) 2-(4-  
(methylthio)phenylsulfonylmethyl)cyclohexyl)pyrrolidin 2-  
one,~~

~~3(R) (3 (trifluoromethyl)phenethyl) 1 ((1S, 2R, 4R/S) 4-  
(isopropylamino) 2-  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin 2 one  
trifluoroacetate~~

~~2(S) (3 (Trifluoromethyl)phenethyl) 1 ((1S, 2R, 4R/S) 4-  
(isopropylamino) 2-  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin 2 one  
trifluoroacetate~~

PH7442 NP  
10/776828

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxazepan-3-yl)-3-(trifluoromethyl)benzamide,~~

~~N-((S)-1-((1S,2R,4R)-4-(dimethylamino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopiperidin-3-yl)-3-(trifluoromethyl)benzamide,~~

~~(R\*)-1-((1S\*,2R\*,4R\*)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-3-((2-(3-(trifluoromethyl)phenyl)-1,3-dioxolan-2-yl)methyl)pyrrolidin-2-one,~~

~~(S\*)-1-((1S\*,2R\*,4R\*)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-3-((2-(3-(trifluoromethyl)phenyl)-1,3-dioxolan-2-yl)methyl)pyrrolidin-2-one,~~

~~(S\*)-3-(2-oxo-2-(3-(trifluoromethyl)phenyl)ethyl)-1-((1S\*,2R\*,4R\*)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one,~~

~~(R\*)-3-(2-oxo-2-(3-(trifluoromethyl)phenyl)ethyl)-1-((1S\*,2R\*,4R\*)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one,~~

~~(R\*)-3-(2-hydroxy-2-(3-(trifluoromethyl)phenyl)ethyl)-1-((1S\*,2R\*,4R\*)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one,~~

~~(S\*)-3-(2-hydroxy-2-(3-(trifluoromethyl)phenyl)ethyl)-1-((1S\*,2R\*,4R\*)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one,~~

PH7442 NP  
10/776828

~~((S\*)) 1 ((1S\*,2R\*,4R\*)) 4 (isopropyl(methyl)amino) 2-~~  
~~(phenylsulfonylmethyl)cyclohexyl) 3 (-2 (methoxyimino) 2 (3-~~  
~~(trifluoromethyl)phenyl)ethyl)pyrrolidin 2-one,~~

~~((R\*)) 1 ((1S\*,2R\*,4R\*)) 4 (isopropyl(methyl)amino) 2-~~  
~~(phenylsulfonylmethyl)cyclohexyl) 3 (-2 (methoxyimino) 2 (3-~~  
~~(trifluoromethyl)phenyl)ethyl)pyrrolidin 2-one,~~

~~1 ((1S\*,2R\*,4R\*)) 4 (amino) 2 (phenylsulfonylmethyl)cyclohexyl) 3-~~  
~~(7 (trifluoromethyl) 1H-benzo[d]imidazol 2-yl)pyrrolidin 2-~~  
~~one,~~

~~1 ((1S\*,2R\*,4R\*)) 4 (isopropylamino) 2-~~  
~~(phenylsulfonylmethyl)cyclohexyl) 3 (7 (trifluoromethyl) 1H-~~  
~~benzo[d]imidazol 2-yl)pyrrolidin 2-one,~~

~~1 ((1S\*,2R\*,4R\*)) 4 (isopropyl(methyl)amino) 2-~~  
~~(phenylsulfonylmethyl)cyclohexyl) 3 (7 (trifluoromethyl) 1H-~~  
~~benzo[d]imidazol 2-yl)pyrrolidin 2-one,~~

~~1 ((1S\*,2R\*,4R\*)) 4 (isopropyl(ethyl)amino) 2-~~  
~~(phenylsulfonylmethyl)cyclohexyl) 3 (7 (trifluoromethyl) 1H-~~  
~~benzo[d]imidazol 2-yl)pyrrolidin 2-one,~~

~~1 ((1S\*,2R\*,4R\*)) 4 (Diethylamino) 2-~~  
~~(phenylsulfonylmethyl)cyclohexyl) 3 (7 (trifluoromethyl) 1H-~~  
~~benzo[d]imidazol 2-yl)pyrrolidin 2-one,~~

~~1 ((1S,2R,4R)) 4 (Isopropyl(methyl)amino) 2-~~  
~~(phenylsulfonylmethyl)cyclohexyl) 3 (naphthalen 1-~~  
~~ylamino)pyrrolidin 2-one,~~

PH7442 NP  
10/776828

3-(Benzo[b]thiophen-3-ylamino)-1-((1S,2R,4R)-4-(  
(isopropyl(methyl)amino)-2-(  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;

(S)-3-(6-chloroquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(  
(isopropyl(methyl)amino)-2-(  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;

(S)-3-(6,8-dichloroquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(  
(isopropyl(methyl)amino)-2-(  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;

~~3,5-Dichloro-N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(  
(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-  
yl)benzamide;~~

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(  
(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-  
(trifluoromethoxy)benzamide;~~

3-((E)-3(R\*)-(trifluoromethyl)styryl)-1-((1S\*,2R\*,4R\*)-4-(  
(isopropyl(methyl)amino)-2-(  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;

~~1-((1S\*,2R\*,4R\*)-4-(isopropyl(methyl)amino)-2-(  
(phenylsulfonylmethyl)cyclohexyl)-3(R\*)-((E/Z)-2-(3-(  
(trifluoromethyl)phenyl)prop-1-enyl)pyrrolidin-2-one;~~

~~N-(1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(  
(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3(R)-  
yl)benzamide;~~



PH7442 NP  
10/776828

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-~~  
~~(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3,5-~~  
~~bis(trifluoromethyl)benzamide;~~

~~2-Amino-N-(1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-~~  
~~(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3(R)-yl)-5-~~  
~~(trifluoromethoxy)benzamide;~~

(R)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-3-(6-  
(trifluoromethyl)quinolin-4-ylamino)pyrrolidin-2-one;

(S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-3-(6-  
(trifluoromethyl)quinolin-4-ylamino)pyrrolidin-2-one;

(R)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-3-(7-  
(trifluoromethyl)quinolin-4-ylamino)pyrrolidin-2-one;

(S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-3-(7-  
(trifluoromethyl)quinolin-4-ylamino)pyrrolidin-2-one;

~~3-(2-(Phenyl)phenylamino)-1-((1S,2R,4R)-4-~~  
~~(isopropyl(methyl)amino)-2-~~  
~~(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;~~

PH7442 NP  
10/776828

~~3-(3,5-Bis(trifluoromethyl)phenylamino)-1-((1S,2R,4R)-4-  
(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one,~~

~~1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-3-(2-  
(trifluoromethyl)phenylamino)pyrrolidin-2-one,~~

~~1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-3-(2-  
methoxyphenylamino)pyrrolidin-2-one,~~

~~1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-3-(3-  
(trifluoromethyl)phenylamino)pyrrolidin-2-one,~~

~~1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-3-(4-  
(trifluoromethyl)phenylamino)pyrrolidin-2-one,~~

~~3-Chloro-N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-  
yl)benzamide,~~

~~3-Fluoro-N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-5-  
(trifluoromethyl)benzamide,~~

~~tert Butyl (1R,3R,4S)-4-((S)-2-oxo-3-(3-  
(trifluoromethyl)benzamido)pyrrolidin-1-yl)-3-  
(phenylsulfonylmethyl)cyclohexylcarbamate,~~

PH7442 NP  
10/776828

~~N ((S) 2 Oxo 1 ((1S,2R,4R) 4 (phenylamino) 2-  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin 3-yl) 3-  
(trifluoromethyl)benzamide,~~

~~N (2 Oxo 1 ((1S,2R,4R) 2 (phenylsulfonylmethyl) 4 (pyridin 4-  
ylamino)cyclohexyl)pyrrolidin 3-yl) 3-  
(trifluoromethyl)benzamide,~~

~~N (2 Oxo 1 ((1S,2R,4R) 2 (phenylsulfonylmethyl) 4 (thiazol-2-  
ylamino)cyclohexyl)pyrrolidin 3-yl) 3-  
(trifluoromethyl)benzamide,~~

~~Methyl (1R,3R,4S) 4 ((S) 2 oxo 3 (3-  
(trifluoromethyl)benzamide)pyrrolidin 1-yl) 3-  
(phenylsulfonylmethyl)cyclohexylcarbamate,~~

~~N ((S) 1 ((1S,2R,4R) 4 Formamido 2-  
(phenylsulfonylmethyl)cyclohexyl) 2-oxopyrrolidin 3-yl) 3-  
(trifluoromethyl)benzamide,~~

~~1 ((1R,3R,4S) 4 ((S) 2 Oxo 3 (3-  
(trifluoromethyl)benzamide)pyrrolidin 1-yl) 3-  
(phenylsulfonylmethyl)cyclohexyl)urea,~~

~~1 Methyl 3 ((1R,3R,4S) 4 ((S) 2 oxo 3 (3-  
(trifluoromethyl)benzamide)pyrrolidin 1-yl) 3-  
(phenylsulfonylmethyl)cyclohexyl)urea,~~

PH7442 NP  
10/776828

~~N ((S) 2-Oxo 1 ((1S,2R,4R) 4 (2-oxopyrrolidin-1-yl) 2-  
(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-3-yl) 3-  
(trifluoromethyl)benzamide,~~

~~N ((S) 1 ((1S,2R,4R) 4 (2,1-dioxo isothiazolidin-2-yl) 2-  
(phenylsulfonylmethyl)cyclohexyl) 2-oxopyrrolidin-3-yl) 3-  
(trifluoromethyl)benzamide,~~

~~N ((S) 1 ((1S,2R,4R) 2 ((4-chlorophenylsulfonyl)methyl) 4-  
(isopropyl(methyl)amino)cyclohexyl) 2-oxopyrrolidin-3-yl) 3-  
fluoro-5-(trifluoromethyl)benzamide,~~

~~3-Chloro-N ((S) 1 ((1S,2R,4R) 2 ((4-chlorophenylsulfonyl)methyl)-  
4-(isopropyl(methyl)amino)cyclohexyl) 2-oxopyrrolidin-3-  
yl)benzamide,~~

~~N ((S) 1 ((1S,2R,4R) 2 ((4-chlorophenylsulfonyl)methyl) 4-  
(isopropyl(methyl)amino)cyclohexyl) 2-oxopyrrolidin-3-yl)-  
3,5-bis(trifluoromethyl)benzamide,~~

~~tert-Butyl 2 (((S) 1 ((1S,2R,4R) 2 ((4-  
chlorophenylsulfonyl)methyl) 4-  
(isopropyl(methyl)amino)cyclohexyl) 2-oxopyrrolidin-3-  
yl)carbamoyl) 4-(trifluoromethoxy)phenylcarbamate,~~

~~2-Amino-N ((S) 1 ((1S,2R,4R) 2 ((4-chlorophenylsulfonyl)methyl) 4-  
(isopropyl(methyl)amino)cyclohexyl) 2-oxopyrrolidin-3-yl) 5-  
(trifluoromethoxy)benzamide,~~

PH7442 NP  
10/776828

~~N-((S)-1-((1S,2R,4R)-2-((4-Chlorophenylsulfonyl)methyl)-4-  
(isopropyl(methyl)amino)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-  
(trifluoromethoxy)benzamide,~~

~~N-((S)-1-((1S,2R,4R)-2-((4-Chlorophenylsulfonyl)methyl)-4-  
(isopropyl(methyl)amino)cyclohexyl)-2-oxopyrrolidin-3-yl)-2-  
(trifluoromethyl)benzamide,~~

~~3,5-Dichloro-N-((S)-1-((1S,2R,4R)-2-((4-  
chlorophenylsulfonyl)methyl)-4-  
(isopropyl(methyl)amino)cyclohexyl)-2-oxopyrrolidin-3-  
yl)benzamide,~~

~~3-Chloro-N-((S)-1-((1S,2R,4R)-2-((4-chlorophenylsulfonyl)methyl)-  
4-(isopropyl(methyl)amino)cyclohexyl)-2-oxopyrrolidin-3-  
yl)benzamide N-Oxide,~~

~~N-((S)-1-((1S,2R,4R)-2-((4-Chlorophenylsulfonyl)methyl)-4-  
(isopropyl(methyl)amino)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-  
(trifluoromethyl)benzamide N-Oxide,~~

~~N-((S)-1-((1S,2R,4R)-2-((4-Chlorophenylsulfonyl)methyl)-4-  
(isopropyl(methyl)amino)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-  
fluoro-5-(trifluoromethyl)benzamide N-Oxide,~~

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-  
(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-  
(trifluoromethyl)benzamide N-Oxide,~~

PH7442 NP  
10/776828

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-((4-isopropylphenylsulfonyl)methyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-(trifluoromethyl)benzamide,~~

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(4-tolylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-(trifluoromethyl)benzamide,~~

~~N-((S)-1-((1S,2R,4R)-2-((4-Fluorophenylsulfonyl)methyl)-4-(isopropyl(methyl)amino)cyclohexyl)-2-oxopyrrolidin-3-yl)-3-(trifluoromethyl)benzamide,~~

~~3-Chloro-N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(tosylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)benzamide,~~

~~2-Amino-N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(tosylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-5-(trifluoromethoxy)benzamidamide,~~

~~1-[(1S, 2R, 4R)-4-Amino-2-benzenesulfonylmethylcyclohexyl]-4-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyridin-2-one,~~

~~1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-isopropylamino-cyclohexyl]-4-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyridin-2-one,~~

~~1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl methyl-amino)cyclohexyl]-4-(3-trifluoromethyl phenyl)-5,6-dihydro-1H-pyridin-2-one,~~

PH7442 NP  
10/776828

~~1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-ethyl-amino)cyclohexyl]-4-(3-trifluoromethyl-phenyl)-5,6-dihydro-1H-pyridin-2-one;~~

1-[(1S, 2R, 4R)-2-Benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-trifluoromethyl-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(7-chloro-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(2,6-dichloro-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-dimethylamino-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-hydroxy-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-trifluoromethyl-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-tert-butyl-thieno[3,2-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

PH7442 NP  
10/776828

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-tert-butyl-2-trifluoromethyl-thieno[3,2-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-tert-butyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-pyrrolidin-2-one;

(3S)-3-(6-Adamantan-1-yl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-pyrrolidin-2-one;

~~3-Methyl-2-phenyl-3H-imidazole-4-carboxylic acid {(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl}-amide;~~

~~1-Methyl-2-phenyl-1H-imidazole-4-carboxylic acid {(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl}-amide;~~

~~3-Benzyl-2-phenyl-3H-imidazole-4-carboxylic acid {(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl}-amide;~~

~~1-Benzyl-2-phenyl-1H-imidazole-4-carboxylic acid {(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl}-amide;~~



PH7442 NP  
10/776828

~~2-Phenyl-3H-imidazole-4-carboxylic acid [(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-amide;~~

~~Preparation of 1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6,7-dimethoxy-quinazolin-4-ylamino)-pyrrolidin-2-one;~~

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-fluoro-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-methyl-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-propyl-pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-isopropyl-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(2-tert-butyl-6-chloro-quinazolin-4-ylamino)-pyrrolidin-2-one;

PH7442 NP  
10/776828

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-methyl-quinazolin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-ethyl-quinazolin-4-ylamino)-pyrrolidin-2-one;

~~N-[(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2,5-dioxo-pyrrolidin-3-yl]-3-trifluoromethyl-benzamide;~~

~~N-[(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-4-adamantan-1-yl-1H-pyrrole-2-carboxamide;~~

~~N-[(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-4-adamantan-1-yl-1-methyl-1H-pyrrole-2-carboxamide;~~

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-tert-butyl-pyrimido[5,4-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

~~5-Bromo-2-tert-butyl-pyrimidine-4-carboxylic acid-[(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-oxo-pyrrolidin-3-yl]-amide;~~

PH7442 NP  
10/776828

~~2-tert Butyl pyrimidine 4 carboxylic acid {(3S\*)-1-[(1S\*, 2R\*, 4R\*)-2-benzenesulfonylmethyl-4-(isopropyl methyl amino)-cyclohexyl]-2-oxo pyrrolidin-3-yl} amide,~~

~~2-tert Butyl 5-phenyl pyrimidine 4 carboxylic acid {(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl methyl amino)-cyclohexyl]-2-oxo pyrrolidin-3-yl} amide,~~

~~N-{(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl methyl amino)-cyclohexyl]-2-oxo pyrrolidin-3-yl}-3-tert-butyl benzamide,~~

~~N-{(3S)-1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl methyl amino)-cyclohexyl]-2-oxo pyrrolidin-3-yl}-3-bromo-5-tert-butyl benzamide,~~

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-trifluoromethyl-pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

PH7442 NP  
10/776828

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-trifluoromethoxy-pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;

1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-methylamino-quinazolin-4-ylamino)-pyrrolidin-2-one;

(3S)-3-(6-Fluoro-quinazolin-4-ylamino)-1-[(1S, 2R, 4R)-4-(isopropyl-methyl-amino)-2-(toluene-4-sulfonylmethyl)-cyclohexyl]-pyrrolidin-2-one;

~~N-[1-[(1S, 2R, 4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-2-exo-pyrrolidin-(3S)-3-yl]-2-chloro-5-trifluoromethyl-benzamide;~~

(S)-3-(6-Bromoquinazolin-4-ylamino)-1-((1S, 2R, 4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;

(S)-3-(6,7-Difluoroquinazolin-4-ylamino)-1-((1S, 2R, 4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;

(S)-3-(6-Methoxyquinazolin-4-ylamino)-1-((1S, 2R, 4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;

((S)-1-((1S, 2R, 4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-3-(quinazolin-4-ylamino)pyrrolidin-2-one;

PH7442 NP  
10/776828

~~3-Phenyl N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)benzamide,~~

(S)-3-(6-Iodoquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one.

~~3-Tert butyl 4-hydroxy N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)benzamide,~~

~~3-Amino-5-tert butyl N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)thiophene-2-carboxamide,~~

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-2-methyl-5-phenylfuran-3-carboxamide,~~

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-5-nitrofuran-2-carboxamide; and~~

~~N-((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-2-oxopyrrolidin-3-yl)-4-phenylthiophene-2-carboxamide.~~

19. (ORIGINAL) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

PH7442 NP  
10/776828

20. (CANCELED) A method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

21. (CANCELED) A method for modulation of MCP-1, MCP-2, MCP-3 and MCP-4, and MCP-5 activity that is mediated by the CCR2 receptor comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

22. (CANCELED) A method for modulation of MCP-1 activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

23. (WITHDRAWN) A method for treating disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, said disorders being selected from osteoarthritis, aneurism, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerularnephritis, asthma, multiple sclerosis, arteriosclerosis, rheumatoid arthritis, restinosis, organ transplantation, and cancer.

24. (WITHDRAWN) The method for treating disorders, of claim 23, wherein said disorders being selected from psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis,

PH7442 NP  
10/776828

glomerularnephritis, asthma, multiple sclerosis, arteriosclerosis, rheumatoid arthritis restinosis, organ transplantation, and cancer.

25. (WITHDRAWN) The method for treating disorders, of claim 24, wherein said disorders being selected from alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerularnephritis, asthma, multiple sclerosis, arteriosclerosis, rheumatoid arthritis restinosis, organ transplantation, and cancer.

26. (WITHDRAWN) The method for treating disorders, of claim 25, wherein said disorders being selected from asthma, multiple sclerosis, arteriosclerosis, and rheumatoid arthritis.

27. (CANCELED) A method for treating inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

28. (CANCELED) A method for modulation of CCR2 activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

29. (WITHDRAWN) The method for treating disorders, of claim 25, wherein said disorders being selected from restinosis, organ transplantation, and cancer.

30. - 36. (CANCELED)

37. (NEW) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 7.

PH7442 NP  
10/776828

38. (NEW) A method for treating disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 7, said disorders being selected from asthma, multiple sclerosis, arteriosclerosis, and rheumatoid arthritis.